{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "bdc25a86",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "USER_AGENT environment variable not set, consider setting it to identify your requests.\n",
      "/home/bionik/miniconda3/envs/LLM/lib/python3.10/site-packages/tqdm/auto.py:21: TqdmWarning: IProgress not found. Please update jupyter and ipywidgets. See https://ipywidgets.readthedocs.io/en/stable/user_install.html\n",
      "  from .autonotebook import tqdm as notebook_tqdm\n"
     ]
    }
   ],
   "source": [
    "import faiss\n",
    "from langchain_ollama import ChatOllama,OllamaEmbeddings\n",
    "from langchain_core.prompts import PromptTemplate\n",
    "from pydantic import BaseModel, Field\n",
    "from langchain_community.document_loaders import WebBaseLoader, PyPDFLoader, TextLoader\n",
    "from langchain_text_splitters import RecursiveCharacterTextSplitter\n",
    "from langchain_community.vectorstores import FAISS\n",
    "import faiss\n",
    "import xml.etree.ElementTree as ET\n",
    "import pyttsx3\n",
    "from langchain_core.output_parsers import PydanticOutputParser,StrOutputParser\n",
    "from typing import List\n",
    "from langchain.agents import create_agent\n",
    "from langchain.agents.middleware import SummarizationMiddleware\n",
    "from langgraph.checkpoint.memory import InMemorySaver\n",
    "from langchain_core.runnables import RunnableConfig\n",
    "import re\n",
    "from langchain_core.runnables import RunnableParallel, RunnablePassthrough\n",
    "import numpy as np\n",
    "from langchain_core.runnables import RunnablePassthrough\n",
    "from langchain_core.prompts import ChatPromptTemplate,SystemMessagePromptTemplate,HumanMessagePromptTemplate\n",
    "from langchain_core.prompts import PromptTemplate\n",
    "import spacy\n",
    "import pickle\n",
    "import requests\n",
    "from scispacy.linking import EntityLinker\n",
    "import scispacy\n",
    "import re\n",
    "from langchain.messages import SystemMessage,HumanMessage,AIMessage,ToolMessage\n",
    "from langchain.tools import tool\n",
    "from langchain_community.docstore.in_memory import InMemoryDocstore\n",
    "import pyobo\n",
    "import time\n",
    "from collections import defaultdict\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "97dbbc35",
   "metadata": {},
   "outputs": [],
   "source": [
    "#linker = pyobo.get_scispacy_entity_linker(\"uniprot\", filter_for_definitions=False, resolve_abbreviations=True)\n",
    "nlp = spacy.load('en_ner_jnlpba_md')\n",
    "nlp.disable_pipes(\"tagger\", \"parser\")\n",
    "nlp.add_pipe(\"sentencizer\")\n",
    "linker = pyobo.get_scispacy_entity_linker(\"hgnc\", filter_for_definitions=False, resolve_abbreviations=True,)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "03fe835f",
   "metadata": {},
   "outputs": [],
   "source": [
    "def fetch_ncbi_data(query):\n",
    "    base_url_esearch='https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi'\n",
    "    params_esearch = {\"db\": \"pubmed\",\"term\": query,\"retmode\": \"json\",\"retstart\": 0,\"retmax\": 10000,'email':'your_email@example.com',\n",
    "              'datetype':'pdat','mindate':'2010/01/01', 'maxdate':'2025/01/01'}\n",
    "    response_esearch=requests.get(base_url_esearch, params=params_esearch)\n",
    "    list_of_pubmed=response_esearch.json()['esearchresult']['idlist']\n",
    "    dois=[]\n",
    "    journal=[]\n",
    "    base_url_efetch='https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi'\n",
    "    for list in [list_of_pubmed[i:i+10]for i in range(0,len(list_of_pubmed),10)]:\n",
    "        query=f\"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi\"\n",
    "        param_efetch={'retmode':'xml',\"db\": \"pubmed\",\"id\": ','.join(list),\"retstart\": 0,\"retmax\": 1000}\n",
    "        response_efetch=requests.get(base_url_efetch,params=param_efetch)\n",
    "        tree = ET.fromstring(response_efetch.text)\n",
    "        base='https://doi.org/'\n",
    "        for i in tree.findall('PubmedArticle/PubmedData/ArticleIdList/ArticleId'):\n",
    "            if i.attrib.get('IdType')=='doi':\n",
    "                dois.append(base+i.text)\n",
    "        for i in tree.findall('PubmedArticle/MedlineCitation/Article/Journal/Title'):\n",
    "            journal.append(i.text)\n",
    "            \n",
    "    return {k: v for k, v in zip(dois, journal)}\n",
    "            "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "21c28e21",
   "metadata": {},
   "outputs": [],
   "source": [
    "query='free full text[filter] AND \"AKT signaling pathway\"[Title/Abstract] AND review[Publication Type] AND (humans[MeSH Terms] AND (\"disease\"[MeSH Terms] OR disease[Title/Abstract]))'\n",
    "dicss=fetch_ncbi_data(query)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "id": "df141d83",
   "metadata": {},
   "outputs": [],
   "source": [
    "all_docs=[]\n",
    "for i in dicss.keys(): \n",
    "    doc=WebBaseLoader(i,requests_kwargs={'allow_redirects': True}).load()[0]\n",
    "    if len(doc.page_content)>2000:\n",
    "        all_docs.append(doc)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 75,
   "id": "80cd4e61",
   "metadata": {},
   "outputs": [],
   "source": [
    "#doc=WebBaseLoader('https://pmc.ncbi.nlm.nih.gov/articles/PMC11554381/').load()\n",
    "cleaned_docs=[]\n",
    "count=0\n",
    "for doc in all_docs:\n",
    "    if 'Reference' in doc.page_content and 'Abstract' in doc.page_content:\n",
    "        references=doc.page_content.split(r'.References')[:-1]\n",
    "        title=doc.metadata['title'].strip()\n",
    "        cleaning=re.sub(r\"\\s+\", \" \", doc.page_content)\n",
    "        cleaning=re.split(r\"Abstract|background\",cleaning)[1]\n",
    "        cleaning=re.split(r\"Acknowledgements\",cleaning)[0]\n",
    "        cleaning=re.sub(r'.Keywords*\\n?',' ',cleaning)\n",
    "        cleaning=re.sub('Open in a new tab','',cleaning)\n",
    "        cleaning=re.sub(r'[\\r\\n]+', r'\\n', cleaning)\n",
    "        cleaning=re.sub(r\"\\s*\\(?\\s*(?:Figure|Fig\\.?)\\s*[\\d.]+\\s*\\)?\\s*\",'',cleaning,flags=re.IGNORECASE).strip()\n",
    "        cleaning=re.sub(r'\\[[\\d\\s\\W]*?\\].','',cleaning,flags=re.IGNORECASE)\n",
    "        cleaning=re.sub(r\"\\(([^)]*?\\s*et\\s*al\\.\\s*[^)]*?)\\)\",'',cleaning)\n",
    "        cleaning=re.sub(r'\\(\\d+(?:,\\d+|-?\\d+)*\\)\\.','.',cleaning)\n",
    "        cleaning=re.sub(r'\\([\\w\\s]+\\d{4},?\\s*[\\dâ€“-]*\\)','',cleaning)\n",
    "        cleaning=re.sub(r\"\\([rR]eviewed in\\)\",'',cleaning,flags=re.IGNORECASE)\n",
    "        cleaning=re.sub(r\"www\\.[^/]+/\",' ',cleaning)\n",
    "        cleaned_nlp=linker(nlp(cleaning))\n",
    "        new_text=cleaning\n",
    "        for i in reversed(cleaned_nlp.ents):\n",
    "            id=i._.kb_ents\n",
    "            if id:\n",
    "                name=linker.kb.cui_to_entity[id[0][0]].canonical_name\n",
    "                new_text = new_text[:i.start_char] + name + ' ' + i.label_ + new_text[i.end_char:]\n",
    "        doc.page_content=new_text\n",
    "        cleaned_docs.append(doc)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 77,
   "id": "44cb432c",
   "metadata": {},
   "outputs": [],
   "source": [
    "splitter = RecursiveCharacterTextSplitter(chunk_size=2000,chunk_overlap=500)\n",
    "chunks=splitter.split_documents(cleaned_docs)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "230263d1",
   "metadata": {},
   "outputs": [],
   "source": [
    "embeddings_model = OllamaEmbeddings(model=\"qwen3-embedding:0.6b\",validate_model_on_init=True)\n",
    "vectorstore=FAISS.from_documents(chunks,embeddings_model)\n",
    "retriever=vectorstore.as_retriever(search_type='similarity',search_kwargs={\"k\": 10, \"fetch_k\": 20})\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 83,
   "id": "e34b8051",
   "metadata": {},
   "outputs": [],
   "source": [
    "vectorstore.save_local(\"/home/bionik/AI_ML/FDA_Project/LLM/faiss_index\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "252be7f8",
   "metadata": {},
   "outputs": [],
   "source": [
    "vectorstore = FAISS.load_local(\n",
    "    \"/home/bionik/AI_ML/FDA_Project/LLM/faiss_index\",\n",
    "    embeddings_model,\n",
    "    allow_dangerous_deserialization=True \n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 84,
   "id": "ddf5ad38",
   "metadata": {},
   "outputs": [],
   "source": [
    "class Triplet(BaseModel):\n",
    "    subject: str = Field(..., description=\"ONE protein or ONE protein complex\")\n",
    "    predicate: str = Field(..., description=\"Relationship between protein entities\")\n",
    "    object: str = Field(..., description=\"ONE protein or ONE protein complex\")\n",
    "\n",
    "class TripletList(BaseModel):\n",
    "    triplets: List[Triplet]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 121,
   "id": "36da34ba",
   "metadata": {},
   "outputs": [],
   "source": [
    "LLM_model = ChatOllama(model=\"qwen3:4b-instruct-2507-q4_K_M\",validate_model_on_init=True)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "7b0213d6",
   "metadata": {},
   "outputs": [],
   "source": [
    "system_template = \"\"\"\n",
    "Use the following pieces of retrieved context to answer the question of research article of biology. \n",
    "If you don't know the answer, genuinely say that you don't know.\n",
    "Use only the information which was provided in this query\n",
    "Keep the answer detailed and precise.\n",
    "\n",
    "Use this context to answer the question:\n",
    "{context}\n",
    "\"\"\"\n",
    "\n",
    "human_message='This is the question: {question}'\n",
    "\n",
    "prompt = ChatPromptTemplate.from_messages([SystemMessagePromptTemplate.from_template(system_template),\n",
    "                                           HumanMessagePromptTemplate.from_template(human_message)])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 116,
   "id": "fb577441",
   "metadata": {},
   "outputs": [],
   "source": [
    "def format_context(retrived_doc):\n",
    "    context=\"\\n\\n\".join([doc.page_content for doc in retrived_doc])\n",
    "    return context\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 117,
   "id": "7d2c14e0",
   "metadata": {},
   "outputs": [],
   "source": [
    "LLM_chain = (\n",
    "    RunnableParallel({\"context\": retriever | format_context, \"question\": RunnablePassthrough()})\n",
    "    | prompt\n",
    "    | LLM_model\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 118,
   "id": "19b04f11",
   "metadata": {},
   "outputs": [],
   "source": [
    "input_data = 'how AKT signaling pathway can be used as therapeutic target'\n",
    "response = LLM_chain.invoke(input_data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 120,
   "id": "c5ae5629",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The AKT (Protein Kinase B) signaling pathway is a critical intracellular signaling cascade involved in regulating key cellular processes such as cell survival, proliferation, growth, metabolism, and apoptosis. Because of its central role in maintaining cellular homeostasis and its frequent dysregulation in cancer, the AKT pathway has emerged as a promising therapeutic target in oncology and other diseases.\n",
      "\n",
      "Hereâ€™s how the AKT signaling pathway can be used as a therapeutic target:\n",
      "\n",
      "---\n",
      "\n",
      "### 1. **In Cancer Therapy: Targeting AKT to Inhibit Tumor Growth and Promote Apoptosis**\n",
      "\n",
      "**Background:**  \n",
      "AKT is frequently hyperactivated in various cancers (e.g., breast, prostate, colorectal, lung, and pancreatic cancers) due to mutations, amplifications, or upstream signaling abnormalities (e.g., PI3K activation). This hyperactivation promotes uncontrolled cell growth and resistance to apoptosis.\n",
      "\n",
      "**Therapeutic Strategies:**\n",
      "\n",
      "- **AKT Inhibitors**  \n",
      "  Small-molecule inhibitors that directly block AKT kinase activity (e.g., MK-2206, ipatasertib, capivasertib) are being developed and tested in clinical trials. These drugs aim to:\n",
      "  - Suppress cell proliferation\n",
      "  - Induce apoptosis\n",
      "  - Sensitize cancer cells to chemotherapy or radiation\n",
      "  - Overcome resistance to conventional therapies\n",
      "\n",
      "- **Combination Therapy**  \n",
      "  AKT inhibitors are often combined with:\n",
      "  - **Chemotherapy** or **targeted therapies** (e.g., PARP inhibitors) to enhance efficacy\n",
      "  - **PI3K inhibitors** (to block upstream activation of AKT)\n",
      "  - **Immune checkpoint inhibitors** (to improve anti-tumor immune responses)\n",
      "\n",
      "> Example: Capivasertib (in combination with olaparib) is approved for certain HER2-negative, PIK3CA-mutant advanced breast cancers, showing improved progression-free survival.\n",
      "\n",
      "---\n",
      "\n",
      "### 2. **Targeting AKT in Metabolic Diseases**\n",
      "\n",
      "**Background:**  \n",
      "AKT is a key regulator of glucose and lipid metabolism. Its activity is central in insulin signaling.\n",
      "\n",
      "**Therapeutic Applications:**\n",
      "\n",
      "- **Type 2 Diabetes and Insulin Resistance**  \n",
      "  Inhibiting AKT in insulin-resistant tissues (like liver or muscle) may improve insulin sensitivity in some contexts, although this is complex due to AKTâ€™s role in promoting glucose uptake.\n",
      "\n",
      "- **Research Focus:**  \n",
      "  Modulating AKT activity in metabolic tissues may help develop drugs that improve glucose homeostasis, though current strategies are more focused on upstream regulators (e.g., GLP-1 receptor agonists).\n",
      "\n",
      "> Note: Inhibiting AKT in insulin signaling tissues may be detrimental, so therapeutic targeting must be tissue-specific and context-dependent.\n",
      "\n",
      "---\n",
      "\n",
      "### - **Targeting AKT in Neurodegenerative Diseases**  \n",
      "AKT signaling is involved in neuronal survival and synaptic plasticity.  \n",
      "- In diseases like Alzheimerâ€™s, reduced AKT activity is linked to impaired neuronal survival.  \n",
      "- **Potential strategy:** Enhancing AKT signaling may protect neurons, but this is still in early research stages.\n",
      "\n",
      "---\n",
      "\n",
      "### 3. **Challenges and Limitations**\n",
      "\n",
      "- **Pathway Complexity and Feedback Loops**  \n",
      "  AKT is downstream of multiple upstream signals (e.g., PI3K, growth factors), and inhibition may trigger compensatory activation of other pathways.\n",
      "\n",
      "- **Tissue-Specific Effects**  \n",
      "  AKT has different roles in different tissues (e.g., pro-survival in cancer vs. pro-growth in normal cells), so off-target effects may lead to toxicity.\n",
      "\n",
      "- **Toxicity Concerns**  \n",
      "  Inhibiting AKT can impair normal cell function (e.g., in heart, immune cells), leading to side effects.\n",
      "\n",
      "- **Resistance Mechanisms**  \n",
      "  Tumors may develop resistance via mutations in AKT or activation of parallel survival pathways.\n",
      "\n",
      "---\n",
      "\n",
      "### 4. **Future Directions**\n",
      "\n",
      "- **Development of Isoform-Specific Inhibitors**  \n",
      "  AKT has three isoforms (AKT1, AKT2, AKT3). Targeting specific isoforms may improve efficacy and reduce side effects.\n",
      "\n",
      "- **Biomarker-Driven Therapy**  \n",
      "  Identifying patients with AKT pathway activation (e.g., PIK3CA mutations, PTEN loss) will allow personalized treatment.\n",
      "\n",
      "- **Combination with Other Pathway Inhibitors**  \n",
      "  Rational combinations (e.g., AKT + mTOR, AKT + CDK4/6) may overcome resistance and improve outcomes.\n",
      "\n",
      "---\n",
      "\n",
      "### Summary\n",
      "\n",
      "âœ… **AKT signaling pathway is a viable therapeutic target**, especially in cancer, where its hyperactivation drives tumor progression and therapy resistance.  \n",
      "âœ… Inhibitors of AKT are in clinical use or development and show promise in combination therapies.  \n",
      "âš ï¸ Careful consideration of tissue-specific effects, feedback loops, and patient selection is essential to ensure safety and efficacy.\n",
      "\n",
      "---\n",
      "\n",
      "**Conclusion:**  \n",
      "The AKT pathway is a powerful therapeutic target due to its central role in cell survival and growth. By developing selective inhibitors and combining them with other treatments, clinicians can improve outcomes in cancer and potentially other diseases. However, success depends on understanding the context of AKT activation and developing strategies to minimize off-target effects.\n",
      "\n",
      "Let me know if you'd like specific examples of drugs, clinical trials, or mechanisms of resistance!\n"
     ]
    }
   ],
   "source": [
    "print(response.content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "aa88b092",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "e3bb3842",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 99,
   "id": "0076efa5",
   "metadata": {},
   "outputs": [],
   "source": [
    "LLM_model = ChatOllama(model=\"qwen3:4b-instruct-2507-q4_K_M\",validate_model_on_init=True)\n",
    "embeddings_model = OllamaEmbeddings(model=\"qwen3-embedding:0.6b\",validate_model_on_init=True)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 102,
   "id": "159888c2",
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.tools import tool\n",
    "\n",
    "@tool(response_format=\"content_and_artifact\")\n",
    "def retrieve_context(query: str):\n",
    "    \"\"\"Retrieve information to help answer a query.\"\"\"\n",
    "    retrieved_docs = vectorstore.similarity_search(query, k=10)\n",
    "    serialized = \"\\n\\n\".join([doc.page_content for doc in retrieved_docs])\n",
    "    return serialized, retrieved_docs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "e5a355b0",
   "metadata": {},
   "outputs": [],
   "source": [
    "checkpointer = InMemorySaver()\n",
    "tools = [retrieve_context]\n",
    "# If desired, specify custom instructions\n",
    "prompt = (\"\"\"\n",
    "You have access to a tool that retrieves context\n",
    "Use the tool to help answer user queries.\n",
    "Use the following pieces of retrieved context to answer the question of research article of biology. \n",
    "Keep the answer detailed and precise.\"\"\")\n",
    "agent = create_agent(LLM_model, tools, system_prompt=prompt,checkpointer=checkpointer,\n",
    "                     middleware=[SummarizationMiddleware(model=LLM_model,trigger=(\"tokens\", 4000),keep=(\"messages\", 10))])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 124,
   "id": "e0c2e65a",
   "metadata": {},
   "outputs": [],
   "source": [
    "query = (\"how AKT signaling pathway can be used as therapeutic target?\")\n",
    "config: RunnableConfig = {\"configurable\": {\"thread_id\": \"1\"}}\n",
    "response=agent.invoke({\"messages\": [{\"role\": \"user\", \"content\": query}]},config)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 127,
   "id": "cfd6c6cd",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The **AKT signaling pathway** (also known as the **PI3K-AKT-mTOR pathway**) is a central regulator of cellular processes such as **cell survival, proliferation, metabolism, and apoptosis**. Due to its critical role in maintaining cellular homeostasis and its frequent dysregulation in diseasesâ€”particularly cancer and metabolic disordersâ€”**AKT signaling has emerged as a key therapeutic target**.\n",
      "\n",
      "Below is a detailed and precise explanation of how the AKT signaling pathway can be used as a therapeutic target, based on current biological and clinical research:\n",
      "\n",
      "---\n",
      "\n",
      "### ðŸ”¬ 1. **Molecular Mechanism of AKT Signaling**\n",
      "\n",
      "The AKT pathway is activated through a cascade:\n",
      "\n",
      "1. **Receptor activation** (e.g., growth factor receptors like EGFR, IGF-1R).\n",
      "2. **Phosphorylation of PI3K** â†’ generates PIP3.\n",
      "3. **PIP3 recruits AKT** to the cell membrane.\n",
      "4. **AKT is phosphorylated** at Thr308 and Ser473 by PDK1 and mTORC2, respectively.\n",
      "5. **Activated AKT** phosphorylates downstream targets (e.g., GSK-3Î², mTOR, FOXO, TSC2), promoting:\n",
      "   - Cell survival (inhibition of apoptosis)\n",
      "   - Protein synthesis (via mTOR)\n",
      "   - Glucose metabolism (glycogen synthesis)\n",
      "   - Angiogenesis (via HIF-1Î±)\n",
      "\n",
      "> Dysregulation (e.g., hyperactivation) of this pathway is linked to **cancer, diabetes, and fibrosis**.\n",
      "\n",
      "---\n",
      "\n",
      "### ðŸ¥ 2. **Therapeutic Targeting in Disease Contexts**\n",
      "\n",
      "#### âœ… A. **Cancer Therapy**\n",
      "- **Rationale**: Hyperactivation of AKT is common in many cancers (e.g., breast, prostate, liver, glioblastoma).\n",
      "- **Mechanisms**:\n",
      "  - Inhibiting AKT phosphorylation blocks pro-survival signals.\n",
      "  - Reduces tumor growth, proliferation, and resistance to chemotherapy.\n",
      "- **Therapeutic Agents**:\n",
      "  - **AKT inhibitors**:\n",
      "    - **Ipatasertib** (targets AKT1/2/3)\n",
      "    - **Capivasertib** (selective for AKT1)\n",
      "    - **MK-2206** (clinical trials in solid tumors)\n",
      "  - **Downstream inhibitors**:\n",
      "    - **mTOR inhibitors** (e.g., everolimus, temsirolimus) suppress AKT-mTOR axis.\n",
      "- **Clinical Evidence**:\n",
      "  - Ipatasertib + paclitaxel in **breast cancer** showed improved progression-free survival.\n",
      "  - Capivasertib + pembrolizumab in **triple-negative breast cancer** (TNBC) demonstrated activity in AKT-mutant tumors.\n",
      "- **Challenges**:\n",
      "  - Feedback loops (e.g., activation of MAPK or IRS1).\n",
      "  - Toxicity (e.g., hyperglycemia, immunosuppression).\n",
      "\n",
      "#### âœ… B. **Liver Fibrosis & Regenerative Medicine**\n",
      "- **Rationale**: AKT activation promotes **hepatic stellate cell (HSC) activation**, a key step in fibrosis.\n",
      "- **Therapeutic Strategy**:\n",
      "  - Inhibiting AKT in HSCs can **suppress fibrogenic activity** and promote resolution of fibrosis.\n",
      "- **Evidence**:\n",
      "  - Quercetin and luteolin (natural compounds) **inhibit AKT phosphorylation** in liver fibrosis models.\n",
      "  - PKSH (a TCM formula) modulates the PI3K-AKT pathway to reduce fibrosis.\n",
      "- **Implication**:\n",
      "  - AKT inhibition may serve as a **dual-purpose strategy**â€”inhibiting tumor growth and reducing fibrosis.\n",
      "\n",
      "#### âœ… C. **Metabolic Diseases (e.g., Diabetes)**\n",
      "- **Rationale**: AKT is a key mediator of insulin signaling.\n",
      "- **Therapeutic Use**:\n",
      "  - Enhancing AKT activity improves glucose uptake in muscle and adipose tissue.\n",
      "  - Inhibiting AKT in insulin-resistant states may improve insulin sensitivity.\n",
      "- **Approach**:\n",
      "  - **Insulin sensitizers** (e.g., metformin, thiazolidinediones) indirectly activate AKT.\n",
      "  - **AKT activators** are being explored in preclinical models.\n",
      "\n",
      "---\n",
      "\n",
      "### ðŸ“Œ 3. **Advantages of Targeting AKT**\n",
      "\n",
      "| Advantage | Explanation |\n",
      "|--------|-------------|\n",
      "| **Central Hub** | AKT sits at the intersection of multiple pathways (growth, survival, metabolism). |\n",
      "| **Disease Relevance** | Dysregulation is observed in >50% of human cancers. |\n",
      "| **Synergy with Other Therapies** | AKT inhibition enhances efficacy of chemotherapy, immunotherapy, and targeted agents. |\n",
      "| **Natural Compound Support** | Compounds like quercetin and luteolin can modulate AKT, offering low-toxicity alternatives. |\n",
      "\n",
      "---\n",
      "\n",
      "### âš ï¸ 4. **Challenges & Limitations**\n",
      "\n",
      "| Challenge | Detail |\n",
      "|--------|--------|\n",
      "| **Feedback Loops** | Inhibiting AKT may trigger compensatory activation of parallel pathways (e.g., MAPK). |\n",
      "| **Toxicity** | AKT is essential for normal cell function; long-term inhibition may cause immunosuppression or metabolic side effects. |\n",
      "| **Tumor Heterogeneity** | AKT activation varies across tumor subtypes and patient populations. |\n",
      "| **Lack of Specific Inhibitors** | Most AKT inhibitors are not highly selective or orally bioavailable. |\n",
      "\n",
      "---\n",
      "\n",
      "### ðŸš€ 5. **Future Directions**\n",
      "\n",
      "- **Combination Therapies**:\n",
      "  - AKT inhibitors + immunotherapy (e.g., anti-PD-1) to overcome resistance.\n",
      "  - AKT inhibitors + chemotherapy to sensitize resistant tumors.\n",
      "- **Personalized Medicine**:\n",
      "  - Biomarker-driven use (e.g., AKT mutations, phosphorylation status in tumor biopsies).\n",
      "- **Natural Product Development**:\n",
      "  - Optimizing TCM compounds (e.g., quercetin, luteolin) to target AKT with minimal side effects.\n",
      "- **Delivery Systems**:\n",
      "  - Nanoparticle-based delivery to target tumor or fibrotic tissue specifically.\n",
      "\n",
      "---\n",
      "\n",
      "### âœ… Conclusion\n",
      "\n",
      "The **AKT signaling pathway is a powerful therapeutic target** due to its central role in cell survival and disease progression. In **cancer**, it is targeted to suppress tumor growth and improve treatment response. In **liver fibrosis**, its inhibition may reduce pathological activation of stellate cells. In **metabolic diseases**, modulating AKT activity can improve insulin sensitivity.\n",
      "\n",
      "> **Key Takeaway**: While AKT inhibition holds significant promise, successful clinical translation requires:\n",
      "> - **Patient stratification** (based on biomarkers),\n",
      "> - **Combination strategies** to avoid resistance,\n",
      "> - And **careful monitoring** of metabolic and immune side effects.\n",
      "\n",
      "If you're designing a research project or clinical trial, consider integrating **AKT phosphorylation status** as a biomarker and testing combinations with existing therapies.\n",
      "\n",
      "Let me know if you'd like a figure (e.g., pathway diagram), a list of approved drugs, or a literature review on AKT inhibitors! ðŸ“š\n"
     ]
    }
   ],
   "source": [
    "#print(response['messages'][-1].content)\n",
    "print(response['messages'][-1].content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 128,
   "id": "4c29a778",
   "metadata": {},
   "outputs": [],
   "source": [
    "query = (\"how this pathway inhibition affect the NFKB(NF-Kappa B) signalling?\")\n",
    "response2=agent.invoke({\"messages\": [{\"role\": \"user\", \"content\": query}]},config)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 140,
   "id": "93bd5726",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "ToolMessage(content='and other therapies (most patients received oral sunitinib as second-line treatment). Of the 28 patients in the study who failed prior treatment with imatinib, 23 were evaluable, and 4 of those patients (17.4%) were progression-free at 4 months. In addition, 47 patients enrolled in the trial had failed treatment with first-line imatinib and second-line sunitinib; among the 35 patients who were evaluable, 13 (37.1%) were progression-free at 4 months. Most patients reported AEs: Sixty-seven percent experienced grade 3 or 4 AEs, and 48% experienced SAEs. These results suggest that patients with GIST may benefit from combined treatment in case of first-line and second-line treatment failure. In another phase 2 study, everolimus was studied in patients with STS or bone sarcoma, but limited clinical efficacy was observed (CR/PR or SD rate, 20%). The most common AEs were skin toxicity, mucositis, and fatigue; serious AEs included pneumonitis and anemia.96 Everolimus is being investigated in 2 other phase 2 trials: 1) a multicenter, triple-arm trial investigating everolimus monotherapy in patients with progressive or metastatic STS or bone sarcoma and in patients with GIST who failed treatment with first-line oral imatinib or second-line oral sunitinib97; and 2) a single-arm, open-label monotherapy trial in patients with resectable STS of the extremities or the retroperitoneum.98 An ongoing phase 2/3 trial is further evaluating the benefit of combined treatment with everolimus and oral imatinib in patients with progressive GIST.99 Ridaforolimus In a phase 2, open-label, nonrandomized trial, patients with advanced sarcomas (N = 212) received a 12.5-mg intravenous dose of ridaforolimus administered daily for 5 days every 2 weeks (Table 1).89 The overall rate of patients achieving a clinical benefit was 29%, including 4 patients who had a confirmed TMEM37 PROTEIN (2 osteosarcomas, 1 spindle cell sarcoma, and 1 malignant fibrous histiocytoma) and 3 patients who had an\\n\\nevents occurred less frequently and were not related to the dose of Tofacitinib used. Filgotinib, a second-generation selective JAK1 PROTEIN inhibitor, has been approved for UC treatment in Europe and Japan.In a randomized, double-blind, phase 2b/3 study,26.1% of UC patients receiving 200mgFilgotinib achieved clinical remission at week 10, which was significantly higher than the remission rate of 15.3% in the placebo group (difference rate, 10.8%; 95% CI: 2.1â€“19.5, P = .0157). Regardless of experience with biologics, was effective in inducing and maintaining clinical remission, and Filgotinib was well tolerated, with a similar incidence of adverse events to the placebo group, with nasopharyngitis and headache being the most common. Upadacitinib has a stronger inhibitory effect on JAK1 PROTEIN. In a phase 2b trial,upadacitinib was used as induction therapy in patients with moderately to severely active UC, and at week 8, clinical responses were achieved in 5.19%, 6.7%, 5.15%, and 30.45% of patients receiving 8.5, 14, 3, and 13 mg, respectively. In contrast, patients who received a placebo did not have clinical remission (P = .052, P = .013, P = .011, and P = .002) and had the best efficacy at 45 mg of upadacitinib once daily. However, the incidence of herpes zoster was higher in patients using upadacitinib, and the study was not sufficient to assess the safety of upadacitinib due to the limitations of the study in terms of sample size, dose range, and duration of use. A subsequent multicenter, phase 3 studyshowed that the clinical remission rate at week 8 was 26% in UC patients receiving induction therapy with upadacitinib at a dose of 45 mg once daily, which was higher than the remission rate of 5% in the placebo group (P < .0001). The rate of clinical remission at week 52 was significantly higher with maintenance upadacitinib at a dose of 30 mg (52%) than with placebo (12%) (P < .0001), and induction and maintenance therapy was well tolerated, and no new safety\\n\\nmainly inhibits JAK1 PROTEIN and JAK3 PROTEIN, and is now approved by the FDA and EMA for the treatment of moderate to severe UC.Animal and human organoid experimentsfound that Tofacitinib may exert clinical effects by reducing the activity of the JAK3 PROTEIN signaling pathway, disrupting the normalization of tight junction protein expression, correcting the function of PTPN2 PROTEIN in macrophages or intestinal epithelial cells, and restoring the integrity of the epithelial barrier. In the subsequent phase III trial to explore its efficacy, it was found that patients with moderate to severe UC who received Tofacitinib clinically had a remission rate of 16.6% at 8 weeks of induction therapy, which was significantly higher than that of 3.6% in the placebo group (P < .001). In the trial with 52-week maintenance therapy, 34.3% of the patients had remission at week 5, as compared with 11.1% of those in the placebo group (P < .001). A real-world studythat included 260 UC patients found that 15.7% of UC patients experienced adverse reactions with Tofacitinib, with infection being the most common, 5.8% of the cohort reported serious adverse events, and 4.2% of the cohort required discontinuation of treatment. An analysis of clinical data from 1157 UC patients foundthat patients treated with Tofacitinib experienced reversible elevated lipid levels during dosing and that lipid levels were negatively correlated with high-sensitivity C-reactive protein levels, but cardiovascular adverse events occurred less frequently and were not related to the dose of Tofacitinib used. Filgotinib, a second-generation selective JAK1 PROTEIN inhibitor, has been approved for UC treatment in Europe and Japan.In a randomized, double-blind, phase 2b/3 study,26.1% of UC patients receiving 200mgFilgotinib achieved clinical remission at week 10, which was significantly higher than the remission rate of 15.3% in the placebo group (difference rate, 10.8%; 95% CI: 2.1â€“19.5, P = .0157). Regardless of\\n\\nof EIF4EBP1 PROTEIN and tumor growth inhibition with temsirolimus.35 These results suggest that decreases in Thr70 phosphorylation of EIF4EBP1 PROTEIN may be a useful surrogate marker for determining inhibition of MTOR PROTEIN activity in tumors. Everolimus (RAD001) Everolimus has demonstrated antiproliferative activity against several tumor cell lines and in a broad range of human tumor xenografts.46-53 In a mouse model of human GIST, everolimus inhibited translational response and cell proliferation in tumor lesions.54 By virtue of its ability to induce cell cycle arrest, these results suggest that everolimus is potentially useful in the treatment of patients with imatinib-resistant GIST. Treatment with everolimus also decelerated tumor growth and prolonged life span in a mouse model of leiomyosarcoma.55 Ridaforolimus (AP23573, MK-8669) Studies of ridaforolimus in human xenograft models of various tumor cell lines (prostate, breast, pancreas, lung, and colon) have demonstrated potent inhibition of tumor growth.56 Ridaforolimus also reduced the rate of cell proliferation in vitro in a panel of 11 sarcoma and 6 endometrial cell lines and inhibited the rate of tumor growth in a leiomyosarcoma xenograft model.57 In another study, sarcoma and endometrial cancer cell lines were treated in vitro with combinations of drugs that included ridaforolimus to determine their antagonistic, additive, or synergistic effects on cell growth.58 The combination of ridaforolimus and doxorubicin demonstrated at least an additive inhibitory effect in 4 sarcoma cell lines. The combination of ridaforolimus with doxorubicin, carboplatin, or paclitaxel as well as the triple combination of carboplatin, paclitaxel, and ridaforolimus had additive effects on 3 endometrial cell lines. Additive growth inhibition of all sarcoma and endometrial cancer cell lines also was observed when ridaforolimus was combined with 2-deoxyglucose, a metabolic inhibitor. Phase 1 Studies The design of phase 1\\n\\nmulticenter, phase 3 studyshowed that the clinical remission rate at week 8 was 26% in UC patients receiving induction therapy with upadacitinib at a dose of 45 mg once daily, which was higher than the remission rate of 5% in the placebo group (P < .0001). The rate of clinical remission at week 52 was significantly higher with maintenance upadacitinib at a dose of 30 mg (52%) than with placebo (12%) (P < .0001), and induction and maintenance therapy was well tolerated, and no new safety risks were observed. 3.5. RBM14 PROTEIN agonists SIP is a membrane-derived lysophospholipid signaling molecule that specifically binds CMKLR2 PROTEIN (SIPR1-SIPR5), and RBM14 PROTEIN agonists target lymphocyte recirculation and block lymphocyte migration from lymphoid organs to the intestine along a chemotactic gradient, thereby effectively reducing intestinal inflammation,leading to the therapeutic drugs Ozanimod and Etrasimod. Ozanimod can optionally combine SIPR1 and SIPR5, and a phase 3, multicenter, randomized, double-blind controlled trialfound that the clinical response rate of induction therapy at week 10 of Ozanimod (18.4%) was significantly higher than that of placebo group (6.0%) (P < .001), and the response rate of maintenance therapy at week 52 (37.0%) was significantly higher than that of the control group (18.5%) (P < .001). Endoscopic changes and mucosal healing were significantly improved, and the incidence of adverse effects was similar in the Ozanimod group and the placebo group, with elevated hepatic aminotransferases being the most common. Etrasimod is a full agonist of S1PR1 PROTEIN and a partial agonist of S1PR4 PROTEIN and S1PR5 PROTEIN, which controls the level of immune cells in the blood and reduces inflammation in the lining of the colon.In the phase 2 randomized trial of patients with moderately to severely active UC,41.8% of UC patients in the Etrasimod2mg group had endoscopic improvement compared with 17.8% of those in the placebo group (P = .003). The\\n\\nhigh-grade glioma, or rhabdomyosarcoma.92 Preliminary data from that trial indicated that 2 patients (1 neuroblastoma, 1 rhabdomyosarcoma) achieved a TMEM37 PROTEIN at 12 weeks and that 11 patients achieved SD that lasted for â‰¥12 weeks.92 Although the trial failed to meet its endpoint of tumor response (at least 2 patients in a subgroup needed to experience objective responses once 12 patients in that group had been enrolled), the responses observed and the clinical benefit attained by some patients suggest that further assessment may be warranted. Several ongoing phase 2 trials are evaluating the benefit of intravenous temsirolimus in patients with various subtypes of sarcoma. Temsirolimus is being investigated as a single agent in patients with STS or GIST93 as well as patients with recurrent or persistent uterine cancer.94 Also, temsirolimus is being evaluated in combination studies with vinorelbine and cyclophosphamide in patients with recurrent or refractory rhabdomyosarcoma,95 and with selumetinib, a TAB1 PROTEIN (MEK) inhibitor, in patients with metastatic, recurrent, or locally advanced unresectable STS.93 Everolimus The oral agent everolimus has been studied as a combination therapy in a phase 2 trial in patients with imatinib-resistant GIST. All patients received everolimus (2.5 mg daily) and imatinib (600 mg daily) (Table 1).87 Patients were enrolled in 2 strata: those who progressed after first-line treatment with oral imatinib and those who progressed after imatinib and other therapies (most patients received oral sunitinib as second-line treatment). Of the 28 patients in the study who failed prior treatment with imatinib, 23 were evaluable, and 4 of those patients (17.4%) were progression-free at 4 months. In addition, 47 patients enrolled in the trial had failed treatment with first-line imatinib and second-line sunitinib; among the 35 patients who were evaluable, 13 (37.1%) were progression-free at 4 months. Most patients reported AEs: Sixty-seven\\n\\nin liver fibrosis. AKT and MTOR PROTEIN, key molecules of the PIK3CA PROTEIN pathway, can inhibit the activation of FUT1 CELL_TYPE and liver fibrosis. Therefore, PKSH may inhibit the activation of FUT1 CELL_TYPE by inhibiting the key molecules AKT and MTOR PROTEIN in the PI3K/AKT signaling pathway, thus inhibiting liver fibrosis. Although network pharmacology has many advantages, it has some limitations. First, the reliability of network pharmacology needs to be further verified for network pharmacology is based on databases and computer analysis. Second, some active drug components identified by network pharmacology do not play important roles in clinical practice. Third, network pharmacology cannot detect the efficacy of drugs, which requires experimental verification. In summary, we demonstrated that PKSH has a notable effect on inhibiting liver fibrosis. The main bioactive components in PKSH, including quercetin and luteolin, could activate the PI3K-Akt signaling pathway by binding with the hub targets of disease and inhibit liver fibrosis. The mechanism of action may regulate the response to oxidative stress through the PI3K-Akt signaling pathway, which may provide insights into drug development and follow-up pharmacologic research for liver fibrosis. Acknowledgments We would like to acknowledge the support of the Department of No. 1 Surgery, The First Hospital Affiliated to Anhui Chinese Medical University, China. Author contributions Conceptualization: Long Huang. Data curation: Long Huang, Qingsheng Yu. Formal analysis: Long Huang, RPS6KA1 CELL_LINE Peng. Funding acquisition: Qingsheng Yu. Investigation: Long Huang. Methodology: Long Huang. Project administration: Long Huang, Qingsheng Yu. Resources: Long Huang, RPS6KA1 CELL_LINE Peng, Zhou Zhen. Software: Long Huang, RPS6KA1 CELL_LINE Peng, Zhou Zhen. Validation: Long Huang, Qingsheng Yu, RPS6KA1 CELL_LINE Peng, Zhou Zhen. Visualization: Long Huang, Zhou Zhen. Writing â€“ original draft: Long Huang, Zhou\\n\\nMolecular docking of the hub targets with bioactive compounds. (A) Binding poses of quercetin complexed with AKT1 PROTEIN, affinity = âˆ’4.5 kcal/mol. (B) Binding poses of luteolin complexed with CCND1 DNA, affinity = âˆ’7.9 kcal/mol. (C) Binding poses of luteolin complexed with EGFR PROTEIN, affinity = âˆ’8.4 kcal/mol. (D) Binding poses of luteolin complexed with MAPK1, affinity = âˆ’9.1 kcal/mol. (E) Binding poses of quercetin complexed with MYC PROTEIN, affinity = âˆ’7.8 kcal/mol. (F) Binding poses of luteolin complexed with RELA PROTEIN, affinity = âˆ’8.4 kcal/mol.4. Discussion The TCM PKSH is widely used to treat liver fibrosis in China; however, its mechanism of action remains unclear. In this study, we screened the core targets of PKSH and constructed a PPI network for the treatment of liver fibrosis. GO and KEGG enrichment analyses were performed to explore potential biological molecular mechanisms and identify biological functions and candidate targets. Through network pharmacological research, the potential pharmacological mechanism of PKSH in treating liver fibrosis was revealed, thereby providing a theoretical basis for subsequent drug development and pharmacological experiments. Through a network pharmacological study of the peach kernel and safflower in the treatment of liver fibrosis, we explored the potential pharmacological mechanism to provide a theoretical basis for subsequent drug research and development. In this study, based on the results of network pharmacology, we speculated that the common ingredient Î²-sitosterol  in PKSH played a coordinating role in the treatment of liver fibrosis. Meanwhile, the main bioactive components, including quercetin and luteolin, could activate the PI3K-Akt signaling pathway by binding with the hub targets of disease and inhibiting liver fibrosis. By observing a Venny diagram of the disease and targets of PKSH, we identified 179 related genes and 15 hub genes. Overlapping genes between the TP53TG3 DNA of active compounds\\n\\ndemonstrated ability to inhibit the growth of MAGEB16 CELL_LINE, P388 leukemia, MiaPaCa-2 cells, and Panc-1 human pancreatic carcinoma in xenograft models.41, 42 Results from the Pediatric Preclinical Testing Program have indicated that sirolimus has broad antitumor activity against in vivo panels of childhood tumors, with noteworthy activity in select sarcoma and acute lymphoblastic leukemia xenografts.43 In addition, recent data from this program, which examined in vivo solid tumor models, including sarcomas (Ewing, osteosarcoma, rhabdomyosarcoma), have demonstrated the therapeutic potential of sirolimus in combination with cytotoxic agents such as cyclophosphamide or vincristine.44 Temsirolimus (CCI-779) In murine xenograft models of rhabdomyosarcoma cell lines (Rh30 and RD), treatment with temsirolimus was effective in inhibiting tumor growth.45 The antitumor activity of temsirolimus was associated with a reduction of HIF-1Î± levels and VEGFA PROTEIN protein expression and with decreased microvessel density in Rh30-derived and RD-derived tumors, demonstrating suppressed tumor growth through an antiangiogenic mechanism. Treatment with a single 20-mg/kg dose of temsirolimus suppressed the phosphorylation of RPS6 PROTEIN and EIF4EBP1 PROTEIN, indicating the inhibition of MTOR PROTEIN activity. In another study that used a rhabdomyosarcoma Rh30 mouse xenograft model, a high correlation coefficient was reported between decreases in phosphorylation of threonine residue 70 (Thr70) of EIF4EBP1 PROTEIN and tumor growth inhibition with temsirolimus.35 These results suggest that decreases in Thr70 phosphorylation of EIF4EBP1 PROTEIN may be a useful surrogate marker for determining inhibition of MTOR PROTEIN activity in tumors. Everolimus (RAD001) Everolimus has demonstrated antiproliferative activity against several tumor cell lines and in a broad range of human tumor xenografts.46-53 In a mouse model of human GIST, everolimus inhibited translational response and cell\\n\\nI2 = 96%, and 82%, respectively). Thereby, random effects model was used for meta-analysis. Compared with the control group, the blood amylase content of the study group was reduced (SMD = âˆ’2.25, 95% CI  P = .003,A). In addition, blood amylase recovery time is significantly shortened (PITX3 PROTEIN = âˆ’2.20, 95% CI  P < .00001,B). For white blood cell recovery time, there was no significant heterogeneity among the studies (P = .98, I2 = 0%), and the fixed effects model was used for analysis. The recovery time of white blood cells in the study group was significantly shorter than that in the control group (PITX3 PROTEIN = âˆ’1.57, 95% CI  P < .00001,C).: Forest plot of effects of Xuebijing in combination with CORT PROTEIN on serum-related indicators. (A) Blood amylase content; (B) blood amylase recovery time; (C) white blood cell recovery time.3.3.5. Inflammatory factor levels Inflammatory factors mainly include CXCL8 PROTEIN (IL6 PROTEIN), CXCL8 PROTEIN (CXCL8 PROTEIN), RELT PROTEIN (LTB CELL_LINE), high-sensitivity C-reactive protein, and CALCA PROTEIN. For inflammatory factors, there were significant heterogeneity among the studies (P < .05, I2 = 97%, 74% and 94% [Aâ€“C]; 73% and 82% [A and B], respectively). Thereby, random effects model was used for meta-analysis. After treatment, the level of inflammatory factors in the study group decreased significantly and was better than that of the control group. There were differences in statistical significance (PITX3 PROTEIN = âˆ’2.57, 95% CI for IL6 PROTEIN, P < .00001,A; SMD = âˆ’0.91, 95% CI for CXCL8 PROTEIN, P < .00001,B; SMD = âˆ’2.00, 95% CI  P < .00001 for TNFÎ±,C; SMD = âˆ’1.57, 95% CI for high-sensitivity C-reactive protein, P < .00001,A and PITX3 PROTEIN = âˆ’2.18, 95% CI for procalcitonin, P < .00001,B, respectively).: Forest plot of effects of Xuebijing in combination with CORT PROTEIN on inflammatory factor levels. (A) CXCL8 PROTEIN (IL6 PROTEIN); (B) interleukin 8 (CXCL8 PROTEIN); (C) RELT PROTEIN (TNF-Î±).: Forest plot', name='retrieve_context', id='edb85033-a08a-4f19-8a1d-8bba09b6b81e', tool_call_id='72ae674f-8e13-4054-ba6c-68c1e6414408', artifact=[{'id': '188fd6cd-4798-4550-a8a9-4f295e70338d', 'metadata': {'source': 'https://doi.org/10.1002/cncr.26361', 'title': 'New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma  - Agulnik - 2012 - Cancer - Wiley Online Library', 'description': 'Clinical trials with the mammalian target of rapamycin (mTOR), alone and in combination with other anticancer agents, including chemotherapy and targeted therapies, have demonstrated potential clinic...', 'language': 'en'}, 'page_content': 'and other therapies (most patients received oral sunitinib as second-line treatment). Of the 28 patients in the study who failed prior treatment with imatinib, 23 were evaluable, and 4 of those patients (17.4%) were progression-free at 4 months. In addition, 47 patients enrolled in the trial had failed treatment with first-line imatinib and second-line sunitinib; among the 35 patients who were evaluable, 13 (37.1%) were progression-free at 4 months. Most patients reported AEs: Sixty-seven percent experienced grade 3 or 4 AEs, and 48% experienced SAEs. These results suggest that patients with GIST may benefit from combined treatment in case of first-line and second-line treatment failure. In another phase 2 study, everolimus was studied in patients with STS or bone sarcoma, but limited clinical efficacy was observed (CR/PR or SD rate, 20%). The most common AEs were skin toxicity, mucositis, and fatigue; serious AEs included pneumonitis and anemia.96 Everolimus is being investigated in 2 other phase 2 trials: 1) a multicenter, triple-arm trial investigating everolimus monotherapy in patients with progressive or metastatic STS or bone sarcoma and in patients with GIST who failed treatment with first-line oral imatinib or second-line oral sunitinib97; and 2) a single-arm, open-label monotherapy trial in patients with resectable STS of the extremities or the retroperitoneum.98 An ongoing phase 2/3 trial is further evaluating the benefit of combined treatment with everolimus and oral imatinib in patients with progressive GIST.99 Ridaforolimus In a phase 2, open-label, nonrandomized trial, patients with advanced sarcomas (N = 212) received a 12.5-mg intravenous dose of ridaforolimus administered daily for 5 days every 2 weeks (Table 1).89 The overall rate of patients achieving a clinical benefit was 29%, including 4 patients who had a confirmed TMEM37 PROTEIN (2 osteosarcomas, 1 spindle cell sarcoma, and 1 malignant fibrous histiocytoma) and 3 patients who had an', 'type': 'Document'}, {'id': '3d79762d-074e-4742-845a-9ebebfcf7296', 'metadata': {'source': 'https://doi.org/10.1097/MD.0000000000035020', 'title': '\\r\\n\\tMedicine\\r\\n', 'language': 'en-US'}, 'page_content': 'events occurred less frequently and were not related to the dose of Tofacitinib used. Filgotinib, a second-generation selective JAK1 PROTEIN inhibitor, has been approved for UC treatment in Europe and Japan.In a randomized, double-blind, phase 2b/3 study,26.1% of UC patients receiving 200mgFilgotinib achieved clinical remission at week 10, which was significantly higher than the remission rate of 15.3% in the placebo group (difference rate, 10.8%; 95% CI: 2.1â€“19.5, P = .0157). Regardless of experience with biologics, was effective in inducing and maintaining clinical remission, and Filgotinib was well tolerated, with a similar incidence of adverse events to the placebo group, with nasopharyngitis and headache being the most common. Upadacitinib has a stronger inhibitory effect on JAK1 PROTEIN. In a phase 2b trial,upadacitinib was used as induction therapy in patients with moderately to severely active UC, and at week 8, clinical responses were achieved in 5.19%, 6.7%, 5.15%, and 30.45% of patients receiving 8.5, 14, 3, and 13 mg, respectively. In contrast, patients who received a placebo did not have clinical remission (P = .052, P = .013, P = .011, and P = .002) and had the best efficacy at 45 mg of upadacitinib once daily. However, the incidence of herpes zoster was higher in patients using upadacitinib, and the study was not sufficient to assess the safety of upadacitinib due to the limitations of the study in terms of sample size, dose range, and duration of use. A subsequent multicenter, phase 3 studyshowed that the clinical remission rate at week 8 was 26% in UC patients receiving induction therapy with upadacitinib at a dose of 45 mg once daily, which was higher than the remission rate of 5% in the placebo group (P < .0001). The rate of clinical remission at week 52 was significantly higher with maintenance upadacitinib at a dose of 30 mg (52%) than with placebo (12%) (P < .0001), and induction and maintenance therapy was well tolerated, and no new safety', 'type': 'Document'}, {'id': 'c17c545b-171c-4440-987a-f6464c2ee1f5', 'metadata': {'source': 'https://doi.org/10.1097/MD.0000000000035020', 'title': '\\r\\n\\tMedicine\\r\\n', 'language': 'en-US'}, 'page_content': 'mainly inhibits JAK1 PROTEIN and JAK3 PROTEIN, and is now approved by the FDA and EMA for the treatment of moderate to severe UC.Animal and human organoid experimentsfound that Tofacitinib may exert clinical effects by reducing the activity of the JAK3 PROTEIN signaling pathway, disrupting the normalization of tight junction protein expression, correcting the function of PTPN2 PROTEIN in macrophages or intestinal epithelial cells, and restoring the integrity of the epithelial barrier. In the subsequent phase III trial to explore its efficacy, it was found that patients with moderate to severe UC who received Tofacitinib clinically had a remission rate of 16.6% at 8 weeks of induction therapy, which was significantly higher than that of 3.6% in the placebo group (P < .001). In the trial with 52-week maintenance therapy, 34.3% of the patients had remission at week 5, as compared with 11.1% of those in the placebo group (P < .001). A real-world studythat included 260 UC patients found that 15.7% of UC patients experienced adverse reactions with Tofacitinib, with infection being the most common, 5.8% of the cohort reported serious adverse events, and 4.2% of the cohort required discontinuation of treatment. An analysis of clinical data from 1157 UC patients foundthat patients treated with Tofacitinib experienced reversible elevated lipid levels during dosing and that lipid levels were negatively correlated with high-sensitivity C-reactive protein levels, but cardiovascular adverse events occurred less frequently and were not related to the dose of Tofacitinib used. Filgotinib, a second-generation selective JAK1 PROTEIN inhibitor, has been approved for UC treatment in Europe and Japan.In a randomized, double-blind, phase 2b/3 study,26.1% of UC patients receiving 200mgFilgotinib achieved clinical remission at week 10, which was significantly higher than the remission rate of 15.3% in the placebo group (difference rate, 10.8%; 95% CI: 2.1â€“19.5, P = .0157). Regardless of', 'type': 'Document'}, {'id': 'ab0361f2-d343-4a0b-abc3-99ea39653ac6', 'metadata': {'source': 'https://doi.org/10.1002/cncr.26361', 'title': 'New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma  - Agulnik - 2012 - Cancer - Wiley Online Library', 'description': 'Clinical trials with the mammalian target of rapamycin (mTOR), alone and in combination with other anticancer agents, including chemotherapy and targeted therapies, have demonstrated potential clinic...', 'language': 'en'}, 'page_content': 'of EIF4EBP1 PROTEIN and tumor growth inhibition with temsirolimus.35 These results suggest that decreases in Thr70 phosphorylation of EIF4EBP1 PROTEIN may be a useful surrogate marker for determining inhibition of MTOR PROTEIN activity in tumors. Everolimus (RAD001) Everolimus has demonstrated antiproliferative activity against several tumor cell lines and in a broad range of human tumor xenografts.46-53 In a mouse model of human GIST, everolimus inhibited translational response and cell proliferation in tumor lesions.54 By virtue of its ability to induce cell cycle arrest, these results suggest that everolimus is potentially useful in the treatment of patients with imatinib-resistant GIST. Treatment with everolimus also decelerated tumor growth and prolonged life span in a mouse model of leiomyosarcoma.55 Ridaforolimus (AP23573, MK-8669) Studies of ridaforolimus in human xenograft models of various tumor cell lines (prostate, breast, pancreas, lung, and colon) have demonstrated potent inhibition of tumor growth.56 Ridaforolimus also reduced the rate of cell proliferation in vitro in a panel of 11 sarcoma and 6 endometrial cell lines and inhibited the rate of tumor growth in a leiomyosarcoma xenograft model.57 In another study, sarcoma and endometrial cancer cell lines were treated in vitro with combinations of drugs that included ridaforolimus to determine their antagonistic, additive, or synergistic effects on cell growth.58 The combination of ridaforolimus and doxorubicin demonstrated at least an additive inhibitory effect in 4 sarcoma cell lines. The combination of ridaforolimus with doxorubicin, carboplatin, or paclitaxel as well as the triple combination of carboplatin, paclitaxel, and ridaforolimus had additive effects on 3 endometrial cell lines. Additive growth inhibition of all sarcoma and endometrial cancer cell lines also was observed when ridaforolimus was combined with 2-deoxyglucose, a metabolic inhibitor. Phase 1 Studies The design of phase 1', 'type': 'Document'}, {'id': '6e226df2-1ed2-48ef-81cd-ff127f2785e8', 'metadata': {'source': 'https://doi.org/10.1097/MD.0000000000035020', 'title': '\\r\\n\\tMedicine\\r\\n', 'language': 'en-US'}, 'page_content': 'multicenter, phase 3 studyshowed that the clinical remission rate at week 8 was 26% in UC patients receiving induction therapy with upadacitinib at a dose of 45 mg once daily, which was higher than the remission rate of 5% in the placebo group (P < .0001). The rate of clinical remission at week 52 was significantly higher with maintenance upadacitinib at a dose of 30 mg (52%) than with placebo (12%) (P < .0001), and induction and maintenance therapy was well tolerated, and no new safety risks were observed. 3.5. RBM14 PROTEIN agonists SIP is a membrane-derived lysophospholipid signaling molecule that specifically binds CMKLR2 PROTEIN (SIPR1-SIPR5), and RBM14 PROTEIN agonists target lymphocyte recirculation and block lymphocyte migration from lymphoid organs to the intestine along a chemotactic gradient, thereby effectively reducing intestinal inflammation,leading to the therapeutic drugs Ozanimod and Etrasimod. Ozanimod can optionally combine SIPR1 and SIPR5, and a phase 3, multicenter, randomized, double-blind controlled trialfound that the clinical response rate of induction therapy at week 10 of Ozanimod (18.4%) was significantly higher than that of placebo group (6.0%) (P < .001), and the response rate of maintenance therapy at week 52 (37.0%) was significantly higher than that of the control group (18.5%) (P < .001). Endoscopic changes and mucosal healing were significantly improved, and the incidence of adverse effects was similar in the Ozanimod group and the placebo group, with elevated hepatic aminotransferases being the most common. Etrasimod is a full agonist of S1PR1 PROTEIN and a partial agonist of S1PR4 PROTEIN and S1PR5 PROTEIN, which controls the level of immune cells in the blood and reduces inflammation in the lining of the colon.In the phase 2 randomized trial of patients with moderately to severely active UC,41.8% of UC patients in the Etrasimod2mg group had endoscopic improvement compared with 17.8% of those in the placebo group (P = .003). The', 'type': 'Document'}, {'id': 'e251e54d-d183-496d-97c9-dbb531cbd201', 'metadata': {'source': 'https://doi.org/10.1002/cncr.26361', 'title': 'New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma  - Agulnik - 2012 - Cancer - Wiley Online Library', 'description': 'Clinical trials with the mammalian target of rapamycin (mTOR), alone and in combination with other anticancer agents, including chemotherapy and targeted therapies, have demonstrated potential clinic...', 'language': 'en'}, 'page_content': 'high-grade glioma, or rhabdomyosarcoma.92 Preliminary data from that trial indicated that 2 patients (1 neuroblastoma, 1 rhabdomyosarcoma) achieved a TMEM37 PROTEIN at 12 weeks and that 11 patients achieved SD that lasted for â‰¥12 weeks.92 Although the trial failed to meet its endpoint of tumor response (at least 2 patients in a subgroup needed to experience objective responses once 12 patients in that group had been enrolled), the responses observed and the clinical benefit attained by some patients suggest that further assessment may be warranted. Several ongoing phase 2 trials are evaluating the benefit of intravenous temsirolimus in patients with various subtypes of sarcoma. Temsirolimus is being investigated as a single agent in patients with STS or GIST93 as well as patients with recurrent or persistent uterine cancer.94 Also, temsirolimus is being evaluated in combination studies with vinorelbine and cyclophosphamide in patients with recurrent or refractory rhabdomyosarcoma,95 and with selumetinib, a TAB1 PROTEIN (MEK) inhibitor, in patients with metastatic, recurrent, or locally advanced unresectable STS.93 Everolimus The oral agent everolimus has been studied as a combination therapy in a phase 2 trial in patients with imatinib-resistant GIST. All patients received everolimus (2.5 mg daily) and imatinib (600 mg daily) (Table 1).87 Patients were enrolled in 2 strata: those who progressed after first-line treatment with oral imatinib and those who progressed after imatinib and other therapies (most patients received oral sunitinib as second-line treatment). Of the 28 patients in the study who failed prior treatment with imatinib, 23 were evaluable, and 4 of those patients (17.4%) were progression-free at 4 months. In addition, 47 patients enrolled in the trial had failed treatment with first-line imatinib and second-line sunitinib; among the 35 patients who were evaluable, 13 (37.1%) were progression-free at 4 months. Most patients reported AEs: Sixty-seven', 'type': 'Document'}, {'id': '0b74c7b0-3ec2-4e8f-8c55-0a292a409cbc', 'metadata': {'source': 'https://doi.org/10.1097/MD.0000000000033593', 'title': '\\r\\n\\tMedicine\\r\\n', 'language': 'en-US'}, 'page_content': 'in liver fibrosis. AKT and MTOR PROTEIN, key molecules of the PIK3CA PROTEIN pathway, can inhibit the activation of FUT1 CELL_TYPE and liver fibrosis. Therefore, PKSH may inhibit the activation of FUT1 CELL_TYPE by inhibiting the key molecules AKT and MTOR PROTEIN in the PI3K/AKT signaling pathway, thus inhibiting liver fibrosis. Although network pharmacology has many advantages, it has some limitations. First, the reliability of network pharmacology needs to be further verified for network pharmacology is based on databases and computer analysis. Second, some active drug components identified by network pharmacology do not play important roles in clinical practice. Third, network pharmacology cannot detect the efficacy of drugs, which requires experimental verification. In summary, we demonstrated that PKSH has a notable effect on inhibiting liver fibrosis. The main bioactive components in PKSH, including quercetin and luteolin, could activate the PI3K-Akt signaling pathway by binding with the hub targets of disease and inhibit liver fibrosis. The mechanism of action may regulate the response to oxidative stress through the PI3K-Akt signaling pathway, which may provide insights into drug development and follow-up pharmacologic research for liver fibrosis. Acknowledgments We would like to acknowledge the support of the Department of No. 1 Surgery, The First Hospital Affiliated to Anhui Chinese Medical University, China. Author contributions Conceptualization: Long Huang. Data curation: Long Huang, Qingsheng Yu. Formal analysis: Long Huang, RPS6KA1 CELL_LINE Peng. Funding acquisition: Qingsheng Yu. Investigation: Long Huang. Methodology: Long Huang. Project administration: Long Huang, Qingsheng Yu. Resources: Long Huang, RPS6KA1 CELL_LINE Peng, Zhou Zhen. Software: Long Huang, RPS6KA1 CELL_LINE Peng, Zhou Zhen. Validation: Long Huang, Qingsheng Yu, RPS6KA1 CELL_LINE Peng, Zhou Zhen. Visualization: Long Huang, Zhou Zhen. Writing â€“ original draft: Long Huang, Zhou', 'type': 'Document'}, {'id': '376e524f-fe97-4572-aeaf-5de5d77e9f3d', 'metadata': {'source': 'https://doi.org/10.1097/MD.0000000000033593', 'title': '\\r\\n\\tMedicine\\r\\n', 'language': 'en-US'}, 'page_content': 'Molecular docking of the hub targets with bioactive compounds. (A) Binding poses of quercetin complexed with AKT1 PROTEIN, affinity = âˆ’4.5 kcal/mol. (B) Binding poses of luteolin complexed with CCND1 DNA, affinity = âˆ’7.9 kcal/mol. (C) Binding poses of luteolin complexed with EGFR PROTEIN, affinity = âˆ’8.4 kcal/mol. (D) Binding poses of luteolin complexed with MAPK1, affinity = âˆ’9.1 kcal/mol. (E) Binding poses of quercetin complexed with MYC PROTEIN, affinity = âˆ’7.8 kcal/mol. (F) Binding poses of luteolin complexed with RELA PROTEIN, affinity = âˆ’8.4 kcal/mol.4. Discussion The TCM PKSH is widely used to treat liver fibrosis in China; however, its mechanism of action remains unclear. In this study, we screened the core targets of PKSH and constructed a PPI network for the treatment of liver fibrosis. GO and KEGG enrichment analyses were performed to explore potential biological molecular mechanisms and identify biological functions and candidate targets. Through network pharmacological research, the potential pharmacological mechanism of PKSH in treating liver fibrosis was revealed, thereby providing a theoretical basis for subsequent drug development and pharmacological experiments. Through a network pharmacological study of the peach kernel and safflower in the treatment of liver fibrosis, we explored the potential pharmacological mechanism to provide a theoretical basis for subsequent drug research and development. In this study, based on the results of network pharmacology, we speculated that the common ingredient Î²-sitosterol  in PKSH played a coordinating role in the treatment of liver fibrosis. Meanwhile, the main bioactive components, including quercetin and luteolin, could activate the PI3K-Akt signaling pathway by binding with the hub targets of disease and inhibiting liver fibrosis. By observing a Venny diagram of the disease and targets of PKSH, we identified 179 related genes and 15 hub genes. Overlapping genes between the TP53TG3 DNA of active compounds', 'type': 'Document'}, {'id': '1dc96a5b-609c-40d8-a73a-9d6ea565246d', 'metadata': {'source': 'https://doi.org/10.1002/cncr.26361', 'title': 'New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma  - Agulnik - 2012 - Cancer - Wiley Online Library', 'description': 'Clinical trials with the mammalian target of rapamycin (mTOR), alone and in combination with other anticancer agents, including chemotherapy and targeted therapies, have demonstrated potential clinic...', 'language': 'en'}, 'page_content': 'demonstrated ability to inhibit the growth of MAGEB16 CELL_LINE, P388 leukemia, MiaPaCa-2 cells, and Panc-1 human pancreatic carcinoma in xenograft models.41, 42 Results from the Pediatric Preclinical Testing Program have indicated that sirolimus has broad antitumor activity against in vivo panels of childhood tumors, with noteworthy activity in select sarcoma and acute lymphoblastic leukemia xenografts.43 In addition, recent data from this program, which examined in vivo solid tumor models, including sarcomas (Ewing, osteosarcoma, rhabdomyosarcoma), have demonstrated the therapeutic potential of sirolimus in combination with cytotoxic agents such as cyclophosphamide or vincristine.44 Temsirolimus (CCI-779) In murine xenograft models of rhabdomyosarcoma cell lines (Rh30 and RD), treatment with temsirolimus was effective in inhibiting tumor growth.45 The antitumor activity of temsirolimus was associated with a reduction of HIF-1Î± levels and VEGFA PROTEIN protein expression and with decreased microvessel density in Rh30-derived and RD-derived tumors, demonstrating suppressed tumor growth through an antiangiogenic mechanism. Treatment with a single 20-mg/kg dose of temsirolimus suppressed the phosphorylation of RPS6 PROTEIN and EIF4EBP1 PROTEIN, indicating the inhibition of MTOR PROTEIN activity. In another study that used a rhabdomyosarcoma Rh30 mouse xenograft model, a high correlation coefficient was reported between decreases in phosphorylation of threonine residue 70 (Thr70) of EIF4EBP1 PROTEIN and tumor growth inhibition with temsirolimus.35 These results suggest that decreases in Thr70 phosphorylation of EIF4EBP1 PROTEIN may be a useful surrogate marker for determining inhibition of MTOR PROTEIN activity in tumors. Everolimus (RAD001) Everolimus has demonstrated antiproliferative activity against several tumor cell lines and in a broad range of human tumor xenografts.46-53 In a mouse model of human GIST, everolimus inhibited translational response and cell', 'type': 'Document'}, {'id': '55d44e3b-3efb-43ef-b660-23283476f634', 'metadata': {'source': 'https://doi.org/10.1097/MD.0000000000040964', 'title': '\\r\\n\\tMedicine\\r\\n', 'language': 'en-US'}, 'page_content': 'I2 = 96%, and 82%, respectively). Thereby, random effects model was used for meta-analysis. Compared with the control group, the blood amylase content of the study group was reduced (SMD = âˆ’2.25, 95% CI  P = .003,A). In addition, blood amylase recovery time is significantly shortened (PITX3 PROTEIN = âˆ’2.20, 95% CI  P < .00001,B). For white blood cell recovery time, there was no significant heterogeneity among the studies (P = .98, I2 = 0%), and the fixed effects model was used for analysis. The recovery time of white blood cells in the study group was significantly shorter than that in the control group (PITX3 PROTEIN = âˆ’1.57, 95% CI  P < .00001,C).: Forest plot of effects of Xuebijing in combination with CORT PROTEIN on serum-related indicators. (A) Blood amylase content; (B) blood amylase recovery time; (C) white blood cell recovery time.3.3.5. Inflammatory factor levels Inflammatory factors mainly include CXCL8 PROTEIN (IL6 PROTEIN), CXCL8 PROTEIN (CXCL8 PROTEIN), RELT PROTEIN (LTB CELL_LINE), high-sensitivity C-reactive protein, and CALCA PROTEIN. For inflammatory factors, there were significant heterogeneity among the studies (P < .05, I2 = 97%, 74% and 94% [Aâ€“C]; 73% and 82% [A and B], respectively). Thereby, random effects model was used for meta-analysis. After treatment, the level of inflammatory factors in the study group decreased significantly and was better than that of the control group. There were differences in statistical significance (PITX3 PROTEIN = âˆ’2.57, 95% CI for IL6 PROTEIN, P < .00001,A; SMD = âˆ’0.91, 95% CI for CXCL8 PROTEIN, P < .00001,B; SMD = âˆ’2.00, 95% CI  P < .00001 for TNFÎ±,C; SMD = âˆ’1.57, 95% CI for high-sensitivity C-reactive protein, P < .00001,A and PITX3 PROTEIN = âˆ’2.18, 95% CI for procalcitonin, P < .00001,B, respectively).: Forest plot of effects of Xuebijing in combination with CORT PROTEIN on inflammatory factor levels. (A) CXCL8 PROTEIN (IL6 PROTEIN); (B) interleukin 8 (CXCL8 PROTEIN); (C) RELT PROTEIN (TNF-Î±).: Forest plot', 'type': 'Document'}])"
      ]
     },
     "execution_count": 140,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "response['messages'][2]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 130,
   "id": "195588b0",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The **inhibition of the AKT signaling pathway** has significant and well-documented effects on the **NF-ÎºB (Nuclear Factor kappa B) signaling pathway**, primarily through **cross-talk and regulatory interactions** between the two. Understanding this interaction is critical in cancer, inflammation, and immune regulation.\n",
      "\n",
      "Below is a **detailed, precise, and scientifically grounded explanation** of how AKT inhibition affects NF-ÎºB signaling:\n",
      "\n",
      "---\n",
      "\n",
      "## ðŸ”¬ 1. **Overview of NF-ÎºB Signaling**\n",
      "\n",
      "NF-ÎºB is a transcription factor that regulates genes involved in:\n",
      "- Inflammation\n",
      "- Immune response\n",
      "- Cell survival\n",
      "- Proliferation\n",
      "- Apoptosis\n",
      "\n",
      "Under resting conditions, NF-ÎºB is sequestered in the cytoplasm by **IÎºB** (inhibitor of ÎºB). Upon activation (e.g., by TNF-Î±, IL-1, or TLR ligands), IÎºB is phosphorylated and degraded, allowing NF-ÎºB to translocate to the nucleus and activate target genes.\n",
      "\n",
      "---\n",
      "\n",
      "## ðŸ”¬ 2. **Cross-Talk Between AKT and NF-ÎºB Pathways**\n",
      "\n",
      "AKT and NF-ÎºB are **interconnected** through **direct and indirect signaling mechanisms**:\n",
      "\n",
      "### âœ… A. **AKT Activates NF-ÎºB**\n",
      "- **Mechanism**:\n",
      "  - AKT phosphorylates and activates **IKK (IÎºB kinase)**.\n",
      "  - IKK phosphorylates IÎºB â†’ IÎºB degradation â†’ NF-ÎºB translocation to nucleus.\n",
      "  - AKT also stabilizes NF-ÎºB by inhibiting its degradation or promoting nuclear retention.\n",
      "- **Evidence**:\n",
      "  - In cancer cells, growth factors (e.g., IGF-1) activate both PI3K-AKT and NF-ÎºB.\n",
      "  - AKT inhibition reduces IÎºB phosphorylation and NF-ÎºB nuclear translocation.\n",
      "- **Functional Outcome**:\n",
      "  - **Enhanced inflammation and cell survival** in tumors.\n",
      "\n",
      "> ðŸ” Example: In breast and colorectal cancers, AKT activation leads to sustained NF-ÎºB activity, promoting tumor progression and resistance to therapy.\n",
      "\n",
      "---\n",
      "\n",
      "### âœ… B. **AKT Inhibition Suppresses NF-ÎºB Activation**\n",
      "\n",
      "When AKT signaling is inhibited (e.g., by pharmacological inhibitors like **Ipatasertib**, **MK-2206**, or **Capivasertib**), the following occurs:\n",
      "\n",
      "| Effect | Mechanism |\n",
      "|------|----------|\n",
      "| **Reduced IKK activation** | AKT-dependent phosphorylation of IKK is diminished â†’ less IÎºB degradation. |\n",
      "| **Impaired NF-ÎºB nuclear translocation** | Less NF-ÎºB reaches the nucleus â†’ reduced transcription of pro-survival and inflammatory genes. |\n",
      "| **Downregulation of NF-ÎºB target genes** | Includes: <br> â€¢ Bcl-2 (anti-apoptotic)<br> â€¢ Survivin<br> â€¢ COX-2 (inflammatory)<br> â€¢ ICAM-1 (immune adhesion)<br> â€¢ VEGF (angiogenesis) |\n",
      "\n",
      "> ðŸ“Œ This suppression leads to **increased apoptosis**, **reduced inflammation**, and **decreased tumor growth**.\n",
      "\n",
      "---\n",
      "\n",
      "## ðŸ¥ 3. **Therapeutic Implications in Disease**\n",
      "\n",
      "### âœ… A. **Cancer Therapy**\n",
      "- **Synergy**:\n",
      "  - AKT inhibition suppresses NF-ÎºB â†’ reduces tumor cell survival and inflammatory microenvironment.\n",
      "  - This enhances sensitivity to chemotherapy and radiation.\n",
      "- **Evidence**:\n",
      "  - In **triple-negative breast cancer (TNBC)**, combining **AKT inhibitors** with **anti-PD-1** immunotherapy improves outcomes due to reduced NF-ÎºB-mediated immune evasion.\n",
      "  - In **colorectal cancer**, AKT inhibition reduces NF-ÎºB-driven inflammation and tumor progression.\n",
      "- **Clinical Relevance**:\n",
      "  - NF-ÎºB is a key mediator of **chemoresistance** and **immune escape**; its suppression by AKT inhibition improves treatment efficacy.\n",
      "\n",
      "### âœ… B. **Inflammatory Diseases**\n",
      "- In conditions like **rheumatoid arthritis** or **inflammatory bowel disease**, NF-ÎºB is hyperactivated.\n",
      "- AKT inhibition may reduce NF-ÎºB activity â†’ dampen inflammation.\n",
      "- However, **systemic AKT inhibition** may have off-target effects due to AKT's role in normal immune function.\n",
      "\n",
      "---\n",
      "\n",
      "## âš ï¸ 4. **Important Considerations & Caveats**\n",
      "\n",
      "| Point | Explanation |\n",
      "|------|------------|\n",
      "| **Context-Dependent Effects** | In some cell types or conditions, NF-ÎºB may be activated independently of AKT (e.g., via TLRs or TNF-Î±). |\n",
      "| **Feedback Loops** | NF-ÎºB can activate AKT indirectly via cytokines (e.g., IL-6), creating a **positive feedback loop**. Inhibiting one may stabilize the other. |\n",
      "| **Dual Role of NF-ÎºB** | While NF-ÎºB promotes tumor survival, it also has anti-inflammatory and protective roles in normal tissues. |\n",
      "\n",
      "> ðŸš© Therefore, **complete NF-ÎºB suppression** via AKT inhibition may have unintended consequences in immune homeostasis.\n",
      "\n",
      "---\n",
      "\n",
      "## ðŸš€ 5. **Future Directions**\n",
      "\n",
      "- **Combination therapies**:\n",
      "  - AKT + NF-ÎºB dual inhibition (e.g., using IKK inhibitors) may be more effective than single-pathway targeting.\n",
      "- **Biomarker-driven approaches**:\n",
      "  - Patients with high baseline NF-ÎºB activity may benefit most from AKT inhibition.\n",
      "- **Tissue-specific delivery**:\n",
      "  - Targeted delivery of AKT inhibitors to tumor microenvironments to minimize systemic NF-ÎºB suppression.\n",
      "\n",
      "---\n",
      "\n",
      "## âœ… Summary: How AKT Inhibition Affects NF-ÎºB\n",
      "\n",
      "| Outcome | Mechanism |\n",
      "|--------|----------|\n",
      "| **Reduced NF-ÎºB activation** | AKT inhibition â†’ less IKK activation â†’ less IÎºB degradation. |\n",
      "| **Impaired nuclear translocation** | NF-ÎºB remains cytoplasmic â†’ no gene expression. |\n",
      "| **Downregulation of pro-survival genes** | Bcl-2, Survivin, COX-2, etc. â†“ â†’ increased apoptosis. |\n",
      "| **Reduced tumor inflammation and immune evasion** | Improved response to immunotherapy. |\n",
      "\n",
      "> ðŸŽ¯ **Conclusion**:  \n",
      "> **Inhibition of AKT signaling suppresses NF-ÎºB activity**, leading to reduced inflammation, increased apoptosis, and enhanced anti-tumor effectsâ€”especially in cancers where both pathways are hyperactive.\n",
      "\n",
      "---\n",
      "\n",
      "If you'd like, I can provide a **diagrammatic summary**, a **table of key genes**, or a **clinical trial reference** on AKT/NF-ÎºB crosstalk in cancer. Let me know! ðŸ“šðŸ”¬\n"
     ]
    }
   ],
   "source": [
    "print(response2['messages'][-1].content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 142,
   "id": "f754e3c2",
   "metadata": {},
   "outputs": [],
   "source": [
    "ans=LLM_model.invoke('how AKT signaling pathway can be used as therapeutic target?')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 145,
   "id": "ac960fd4",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The AKT (Protein Kinase B) signaling pathway is a central regulator of cell survival, growth, proliferation, metabolism, and apoptosis. Its dysregulation is commonly associated with cancer, diabetes, and other diseases. Because of its critical role in cellular functions, the AKT pathway has emerged as a promising therapeutic target. Here's how AKT signaling can be used as a therapeutic target across various diseases:\n",
      "\n",
      "---\n",
      "\n",
      "### 1. **In Cancer Therapy**\n",
      "\n",
      "AKT is frequently hyperactivated in many cancers (e.g., breast, prostate, colorectal, lung, and pancreatic cancers), often due to upstream mutations (e.g., PI3K mutations, PTEN loss, or growth factor receptor activation).\n",
      "\n",
      "**Therapeutic Strategies:**\n",
      "\n",
      "- **AKT Inhibitors**:\n",
      "  - Small-molecule inhibitors (e.g., **Ipatasertib**, **Capivasertib**, **MK-2206**) directly inhibit AKT kinase activity.\n",
      "  - These drugs block downstream signaling, leading to reduced cell proliferation and increased apoptosis in cancer cells.\n",
      "  - Used in combination with other therapies (e.g., chemotherapy, immunotherapy, or targeted agents) to enhance efficacy.\n",
      "\n",
      "- **Combination Therapies**:\n",
      "  - AKT inhibitors are often combined with:\n",
      "    - **PI3K inhibitors** (to block upstream activation).\n",
      "    - **mTOR inhibitors** (to target downstream effectors).\n",
      "    - **Hormonal therapies** (e.g., in breast cancer).\n",
      "    - **Immune checkpoint inhibitors** (to improve immune response by reducing tumor cell survival signals).\n",
      "\n",
      "- **Biomarker-Driven Treatment**:\n",
      "  - Patients with tumors exhibiting AKT pathway activation (e.g., PTEN loss, PIK3CA mutations) are more likely to respond to AKT inhibitors.\n",
      "  - Clinical trials are ongoing to identify predictive biomarkers for patient selection.\n",
      "\n",
      "> Example: Capivasertib (an AKT inhibitor) received FDA approval for certain types of advanced breast cancer with PIK3CA or AKT1 mutations.\n",
      "\n",
      "---\n",
      "\n",
      "### 2. **In Metabolic Disorders (e.g., Type 2 Diabetes)**\n",
      "\n",
      "AKT is a key mediator of insulin signaling. Impaired AKT activation contributes to insulin resistance.\n",
      "\n",
      "**Therapeutic Strategies:**\n",
      "\n",
      "- **Enhancing AKT Activity**:\n",
      "  - Drugs that improve insulin sensitivity or activate AKT (e.g., **insulin sensitizers** like metformin, thiazolidinediones) indirectly promote AKT signaling.\n",
      "  - Research is ongoing into compounds that specifically activate AKT without causing hyperglycemia or side effects.\n",
      "\n",
      "- **Targeting AKT in Insulin Resistance**:\n",
      "  - Modulating AKT activity may improve glucose uptake in muscle and adipose tissue, helping manage blood sugar levels.\n",
      "\n",
      "> Note: While direct AKT activation is desirable, it must be carefully controlled due to the risk of promoting cell growth (e.g., tumor development).\n",
      "\n",
      "---\n",
      "\n",
      "### -3. **In Neurodegenerative Diseases**\n",
      "\n",
      "AKT signaling supports neuronal survival and synaptic plasticity. Reduced AKT activity is linked to Alzheimerâ€™s and Parkinsonâ€™s diseases.\n",
      "\n",
      "**Therapeutic Strategies:**\n",
      "\n",
      "- **Neuroprotective Agents**:\n",
      "  - Compounds that activate AKT may help protect neurons from degeneration.\n",
      "  - Research is exploring AKT activators (e.g., via growth factors like IGF-1) for neuroprotection in early-stage neurodegeneration.\n",
      "\n",
      "> Challenges: Delivery to the brain and potential off-target effects remain significant hurdles.\n",
      "\n",
      "---\n",
      "\n",
      "### 4. **In Cardiovascular Diseases**\n",
      "\n",
      "AKT is involved in cardioprotection, cell survival, and angiogenesis.\n",
      "\n",
      "- **AKT activation** can protect heart tissue during ischemia-reperfusion injury.\n",
      "- Drugs that modulate AKT may be useful in heart failure or myocardial infarction, though this area is still under investigation.\n",
      "\n",
      "---\n",
      "\n",
      "### Challenges and Considerations\n",
      "\n",
      "- **Dual Role of AKT**: While AKT promotes survival in normal cells, it can also drive tumor growth. Inhibiting AKT may have unintended consequences (e.g., promoting cell death in healthy tissues).\n",
      "- **Feedback Loops**: Inhibiting AKT can trigger compensatory activation of other pathways (e.g., mTOR, MAPK), reducing efficacy.\n",
      "- **Tumor Heterogeneity**: Not all tumors rely on AKT signaling, so patient stratification is essential.\n",
      "- **Toxicity and Off-Target Effects**: AKT is involved in many physiological processes; long-term inhibition may lead to side effects.\n",
      "\n",
      "---\n",
      "\n",
      "### Future Directions\n",
      "\n",
      "- **Precision Medicine**: Develop biomarkers to identify patients most likely to benefit from AKT-targeted therapy.\n",
      "- **Combination Regimens**: Pair AKT inhibitors with other targeted agents to overcome resistance.\n",
      "- **Next-Gen Inhibitors**: Design more selective, brain-penetrant, or tissue-specific AKT modulators.\n",
      "- **Dual Targeting**: Develop drugs that simultaneously inhibit AKT and upstream activators (e.g., PI3K) or downstream effectors (e.g., mTOR).\n",
      "\n",
      "---\n",
      "\n",
      "### Conclusion\n",
      "\n",
      "The AKT signaling pathway is a powerful therapeutic target due to its central role in disease pathogenesis. In cancer, AKT inhibitors are already in clinical use and show promise in personalized therapy. In metabolic and neurological diseases, AKT modulation offers potential, though more research is needed. Success will depend on understanding context-specific roles of AKT and developing safe, effective, and targeted interventions.\n",
      "\n",
      "âœ… **Bottom Line**: AKT inhibition (in cancer) or activation (in metabolic/neurological disorders) represents a viable and evolving therapeutic strategyâ€”tailored to disease context and patient profile.\n",
      "\n",
      "--- \n",
      "\n",
      "Let me know if you'd like specific drug examples, clinical trial data, or mechanisms of resistance!\n"
     ]
    }
   ],
   "source": [
    "print(ans.content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 146,
   "id": "a32b3e8f",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(id='25211740-6305-49b2-a4a8-84c2884f1911', metadata={'source': 'https://doi.org/10.1097/MD.0000000000033593', 'title': '\\r\\n\\tMedicine\\r\\n', 'language': 'en-US'}, page_content='Bubble chart. BP = biological process, CC = cellular component, GO = Gene Ontology, MF = molecular function.Furthermore, we selected the first 30 KEGG pathways for analysis, and the following KEGG pathways were identified: Lipid and atherosclerosis signaling pathway , human cytomegalovirus infection signaling pathway , PI3K-Akt signaling pathway , Kaposi sarcoma-associated herpesvirus infection signaling pathway , and chemical carcinogenesis receptor activation signaling pathway .: KEGG pathway enrichment analysis of the target proteins. (A) BFAR DNA chart. (B) Bubble chart. KEGG = Kyoto Encyclopedia of Genes and Genomes.3.6. Docking simulation verification AutoDockTools version 1.5.6 was used for molecular docking verification. Molecular docking analysis was used to validate the potential binding of the bioactive components in PKSH to disease-related targets. Because the PI3K-Akt signaling pathway was enriched in liver fibrosis disease in network pharmacology, we focused on the hub targets in the PI3K-Akt signaling pathway. Hub targets, including AKT1 PROTEIN, CCND1 PROTEIN, EGFR PROTEIN, MAPK1, MYC, and RELA PROTEIN, which were involved in the PI3K-Akt signaling pathway, were screened as intersecting targets and considered candidate genes for molecular docking. We used the main bioactive components, including quercetin and luteolin, to bind to the hub targets of the disease. The affinities of the combination of bioactive components and hub targets above are shown in: Molecular docking of the hub targets with bioactive compounds. (A) Binding poses of quercetin complexed with AKT1 PROTEIN, affinity = âˆ’4.5 kcal/mol. (B) Binding poses of luteolin complexed with CCND1 DNA, affinity = âˆ’7.9 kcal/mol. (C) Binding poses of luteolin complexed with EGFR PROTEIN, affinity = âˆ’8.4 kcal/mol. (D) Binding poses of luteolin complexed with MAPK1, affinity = âˆ’9.1 kcal/mol. (E) Binding poses of quercetin complexed with MYC PROTEIN, affinity = âˆ’7.8 kcal/mol. (F) Binding poses of'),\n",
       " Document(id='f859ef09-834b-42f1-bdfa-9a10350bd8ee', metadata={'source': 'https://doi.org/10.1097/MD.0000000000040964', 'title': '\\r\\n\\tMedicine\\r\\n', 'language': 'en-US'}, page_content='123 items, including AKT1 PROTEIN activity, PTK7 PROTEIN activity, PTPMT1 PROTEIN binding, DNAJC12 PROTEIN specific bingding, kinase binding, etcB). Cellular component: got 86 entries, including membrane raft, side of membrane, vesicle lumen, receptor complex, focal adhesion, etcC). KEGG enrichment (KEGG): 186 pathways were identified in the KEGG pathway analysis. The results showed that the proteins were more enriched in cancer signaling pathway, lipid and atherosclerosis, PI3Kâ€“AKT1 PROTEIN signaling pathway, SETD2 PROTEIN signaling pathway, and TNF PROTEIN signaling pathway, indicating that the active components of CSS can interfere with AP through these pathwayD and Table S7, Supplemental Digital Content, https://links.lww.com/MD/O185).: GO bioanalysis and KEGG enrichment analysis of AP treatment. (A, B, and C) GO enrichment analysis of treating CGN targets. (D) KEGG enrichment analysis of treating AP target. AP = acute pancreatitis, GO = Gene Ontology, KEGG = Kyoto Encyclopedia of Genes and Genomes.4. Discussion AP takes systemic inflammatory reaction as the main clinical symptom, which has the characteristics of rapid onset and high mortality. About 20% of patients with AP are severe pancreatitis. According to the course of the disease, it can be divided into acute reaction period, systemic infection period, and residual infection period. During the acute reaction period, if the level of MROCKI PROTEIN in the patientâ€™s pancreas is not effectively controlled, it is very easy to cause systemic inflammatory response syndrome, which can lead to multiple organ failure. It is an important factor leading to the death of patients with AP. Therefore, clinical treatment of patients should focus on controlling the level of inflammatory factors. XBJ added on the basis of conventional treatment has a potential benefit for improving the outcomes of AP.The control group for this article was not fixed. In this study, the control group was treated with somatostatin alone for'),\n",
       " Document(id='a64ca2ee-c589-40a9-9d45-15fbcc1d4104', metadata={'source': 'https://doi.org/10.1186/s11658-022-00308-w', 'title': 'The probable role and therapeutic potential of the PI3K/AKT signaling pathway in SARS-CoV-2 induced coagulopathy | Cellular & Molecular Biology Letters', 'description': 'Coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is associated with a high mortality r', 'language': 'en'}, page_content='and thrombus formation through restricting thromboxane SGCA PROTEIN synthesis and MAPK1 PROTEIN (EPHB2 PROTEIN) phosphorylation  Additionally, loureirin, a flavonoid extracted from dragonâ€™s blood (a deep red resin secreted from Dracaena), has been shown to suppress PPBP PROTEIN activation through PI3K/AKT signaling pathway inhibition AKT is the major downstream effector of PIK3CA PROTEIN in platelets. The PIP3-binding domain of AKT recruits it to the platelet plasma membrane, where it is activated by mammalian target of rapamycin (mTOR) and PDHA1 PROTEIN (PDK1)  AKT plays a central role in platelet activation as downstream target of a variety of receptors such as IGF-1 receptor  All three AKT isoformsâ€”AKT1 PROTEIN, AKT2, and AKT3â€”are expressed in human and mouse platelets, and their role in platelet activation has been elucidated in different studies. Increased bleeding time, and impaired PPBP CELL_TYPE aggregation, secretion and spreading in response to different agonists have been shown in AKT1 PROTEIN KO mice  AKT2 PROTEIN is required for ITGA2 PROTEIN activation and aggregation, and granule secretion induced by Gq induction by low doses of TxA2 and thrombin. Additionally, AKT2 KO platelets show diminished arterial thrombus generation  Regarding AKT3, it has been proposed that it plays a crucial role in mediating granule secretion and PPBP CELL_TYPE aggregation stimulated by TxA2 and thrombin  Also, AKT3 PROTEIN is responsible for NEK3 PROTEIN (GSK-3) inactivation caused by thrombin, leading to arterial thrombosis in vivo PI3K/AKT pathway and PROC PROTEINâ€™ expression and functionAs described above, alterations in levels of several PROC PROTEIN have been detected in samples from COVID-19 patients. Here we examine the role of PI3K/AKT signaling pathways in regulation of these factorsâ€™ expression and activity.TF PROTEIN, a member of the cytokine receptor superfamily, is considered as an initiator of coagulation in different conditions such as blood vessel damage'),\n",
       " Document(id='0b74c7b0-3ec2-4e8f-8c55-0a292a409cbc', metadata={'source': 'https://doi.org/10.1097/MD.0000000000033593', 'title': '\\r\\n\\tMedicine\\r\\n', 'language': 'en-US'}, page_content='in liver fibrosis. AKT and MTOR PROTEIN, key molecules of the PIK3CA PROTEIN pathway, can inhibit the activation of FUT1 CELL_TYPE and liver fibrosis. Therefore, PKSH may inhibit the activation of FUT1 CELL_TYPE by inhibiting the key molecules AKT and MTOR PROTEIN in the PI3K/AKT signaling pathway, thus inhibiting liver fibrosis. Although network pharmacology has many advantages, it has some limitations. First, the reliability of network pharmacology needs to be further verified for network pharmacology is based on databases and computer analysis. Second, some active drug components identified by network pharmacology do not play important roles in clinical practice. Third, network pharmacology cannot detect the efficacy of drugs, which requires experimental verification. In summary, we demonstrated that PKSH has a notable effect on inhibiting liver fibrosis. The main bioactive components in PKSH, including quercetin and luteolin, could activate the PI3K-Akt signaling pathway by binding with the hub targets of disease and inhibit liver fibrosis. The mechanism of action may regulate the response to oxidative stress through the PI3K-Akt signaling pathway, which may provide insights into drug development and follow-up pharmacologic research for liver fibrosis. Acknowledgments We would like to acknowledge the support of the Department of No. 1 Surgery, The First Hospital Affiliated to Anhui Chinese Medical University, China. Author contributions Conceptualization: Long Huang. Data curation: Long Huang, Qingsheng Yu. Formal analysis: Long Huang, RPS6KA1 CELL_LINE Peng. Funding acquisition: Qingsheng Yu. Investigation: Long Huang. Methodology: Long Huang. Project administration: Long Huang, Qingsheng Yu. Resources: Long Huang, RPS6KA1 CELL_LINE Peng, Zhou Zhen. Software: Long Huang, RPS6KA1 CELL_LINE Peng, Zhou Zhen. Validation: Long Huang, Qingsheng Yu, RPS6KA1 CELL_LINE Peng, Zhou Zhen. Visualization: Long Huang, Zhou Zhen. Writing â€“ original draft: Long Huang, Zhou'),\n",
       " Document(id='62e6b046-5b3a-4afe-81e6-eeb9396484a3', metadata={'source': 'https://doi.org/10.1097/MD.0000000000038508', 'title': '\\r\\n\\tMedicine\\r\\n', 'language': 'en-US'}, page_content='The PI3K/AKT signaling pathway triggers mammalian target of rapamycin complex C1 (mTORC1) activation, a crucial downstream effector, through phosphorylation-induced inhibition of TSC2 PROTEIN (TSC2 DNA), TSC2 DNA facilitates the transformation of Ras-related GTPase Rheb from its active Rheb-GTP state to the inactive Rheb-GDP form, active Rheb-GTP effectively activates mTORC1, thereby positioning the TSC complex, which includes TSC2 DNA, as an inhibitor of mTORC1. activated CRTC1 PROTEIN acts to suppress RPS6KB1 PROTEIN and EIF4EBP1P1 PROTEIN, promoting ribosome and protein synthesis involved in the synthesis metabolism of proteins, lipids, nucleotides, and more. Additionally, AKT phosphorylation leads to the inactivation of TCEAL1 PROTEIN and p27, promoting cell proliferation, and negatively regulates apoptosis by blocking the activity of pro-apoptotic factors Bax, BAD PROTEIN, and Forkhead box protein O transcription factors: The classic signaling pathways PI3K/AKT/mTOR and Ras/Raf/MEK/ERK MAPK, along with their STAP1 PROTEIN and mediated cellular processes. In quiescent cells, PTEN PROTEIN maintains low levels of PSME3IP1 PROTEIN, leading to AKT inactivation. Activated RTK (ligands: INSL5 PROTEIN, growth factors, hormones) and GPBAR1 PROTEIN (CCL15 PROTEIN) recruit and activate PIK3CA PROTEIN, which catalyzes the conversion of PIP2 to PSME3IP1 PROTEIN. PSME3IP1 PROTEIN recruits AKT and PDK1 PROTEIN to the membrane via their PH domains, followed by phosphorylation of AKT at T308 and S473 by PDK1 PROTEIN and CRTC2 PROTEIN, respectively. Activated AKT activates or inhibits STAP1 PROTEIN (GSKÎ², mTORC1, p27, p21, Bad, FOXO6 PROTEIN, etc.) through phosphorylation to participate in cell proliferation and metabolism. PTEN PROTEIN and INPP4B PROTEIN negatively regulate AKT activity by dephosphorylating PSME3IP1 PROTEIN and PI-3,4-P2. Additionally, SET PROTEIN and PHLPP1 PROTEIN dephosphorylate AKT at T308 and S473, respectively. CRTC1 PROTEIN participates in negative'),\n",
       " Document(id='0751f546-0716-4023-ba11-3c1aeeef5f58', metadata={'source': 'https://doi.org/10.1111/1753-0407.13252', 'title': 'Targeting the PI3K/Akt signaling pathway in pancreatic Î²â€cells to enhance their survival and function: An emerging therapeutic strategy for type 1 diabetes - Camaya - 2022 - Journal of Diabetes - Wiley Online Library', 'description': 'Highlights\\nPhosphoinositide 3-kinase (PI3K)/Akt signaling is an emerging promising therapeutic target for diabetes.\\nModulation of the PI3K/Akt signaling pathway, via protein and peptide-based biologi...', 'language': 'en'}, page_content='function and prevent death without concomitantly inducing proliferation unlike several other identified stimulators of PI3K/Akt signaling . As such, FhHDM-1 will inform the design of biologics aimed at targeting the PI3K/Akt pathway to prevent/ameliorate not only T1D but also T2D, which is now widely recognized as an inflammatory disease characterized by Î²-cell dysfunction and death. This review will explore the modulation of the PI3K/Akt signaling pathway as a novel strategy to enhance Î²-cell function and survival.'),\n",
       " Document(id='1edfea7b-353f-413f-ab93-0d6459646bb5', metadata={'source': 'https://doi.org/10.1186/s11658-022-00308-w', 'title': 'The probable role and therapeutic potential of the PI3K/AKT signaling pathway in SARS-CoV-2 induced coagulopathy | Cellular & Molecular Biology Letters', 'description': 'Coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is associated with a high mortality r', 'language': 'en'}, page_content='in patients with SARS-CoV-2 infection: pathogenesis and management strategies. Ann Hematol. 2020; 1â€“13.Martini M, De Santis MC, Braccini L, Gulluni F, Hirsch E. PI3K/AKT signaling pathway and cancer: an updated review. Ann Med. 2014;46(6):372â€“83.Article CAS PubMed Google Scholar Huang J, Xia C, Zheng X, Yi T, Wang X, Song G, et al. 17Î²-Estradiol promotes cell proliferation in rat osteoarthritis model chondrocytes via PI3K/Akt pathway. Cell Mol Biol Lett. 2011;16(4):564â€“75.Article CAS PubMed PubMed Central Google Scholar Chen Z, Li T, Kareem K, Tran D, Griffith BP, Wu ZJ. The role of PI3K/Akt signaling pathway in non-physiological shear stress-induced PPBP PROTEIN activation. Artif Organs. 2019;43(9):897â€“908.Article CAS PubMed PubMed Central Google Scholar Guidetti GF, Canobbio I, Torti M. PI3K/Akt in platelet integrin signaling and implications in thrombosis. Adv Biol Regul. 2015;59:36â€“52.Article CAS PubMed Google Scholar Pelzl L, Singh A, Funk J, Witzemann A, Zlamal J, Marini I, et al. Platelet activation via PI3K/AKT signaling pathway in COVID-19. Res Pract Thromb Haemostasis. 2021.Kindrachuk J, Ork B, Mazur S, Holbrook MR, Frieman MB, Traynor D, et al. Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis. Antimicrob Agents Chemother. 2015;59(2):1088â€“99.Article PubMed PubMed Central CAS Google Scholar Mizutani T, Fukushi S, Ishii K, Sasaki Y, Kenri T, Saijo M, et al. Mechanisms of establishment of persistent SARS-CoV-infected cells. Biochem Biophys Res Commun. 2006;347(1):261â€“5.Article CAS PubMed PubMed Central Google Scholar Mizutani T, Fukushi S, Saijo M, Kurane I, Morikawa S. MAPK8 PROTEIN and PI3k/Akt signaling pathways are required for establishing persistent SARS-CoV infection in Vero E6 cells. Biochimica et Biophysica Acta BBA Mol Basis Dis. 2005;1741(1â€“2):4â€“10.Article CAS Google Scholar Sun F, BLOC1S5 DNA, Kwok HF, Xu J, Wu Y, Liu W, et'),\n",
       " Document(id='4cbbff71-86dc-4397-ad2e-05c89acc135a', metadata={'source': 'https://doi.org/10.1097/MD.0000000000038508', 'title': '\\r\\n\\tMedicine\\r\\n', 'language': 'en-US'}, page_content='structural domains I, II, III, and IV), a short transmembrane structural domain (TM), and an intracellular tyrosine kinase domain (containing the catalytic tyrosine kinase structural domain (TK) and the carboxy-terminal tail). Structural domains I and III of the extracellular ligand-binding domains are involved in ligand binding (except for the structural domain of ERBB2 PROTEIN), and structural domains II and IV are two SPARC PROTEIN. The carboxy-terminal tail of the intracellular tyrosine kinase domain has several tyrosine residues that can be phosphorylated. Created with BioRender.com. ERBB2 PROTEIN = ERBB2 PROTEIN CDK16 PROTEIN AKT, commonly referred to as AKT1 PROTEIN (AKT1 PROTEIN), is denoted as AKT and is divided into 3 isoforms: AKT1 PROTEIN, AKT2, and AKT3, and composed of 3 conservative structural domains (the N-terminal PH structural domain, the central kinase structural domain, and a short C-terminal tail) and is a critical member in the PIK3CA PROTEIN signaling pathway.Activation of AKT involves conformational changes and phosphorylation. Its typical pathway for its activation is through stimulation of RET PROTEIN (MED12 PROTEIN) or CMKLR2 PROTEIN (GPCRs), causing activation of the class I PI3K family, which in consequence catalyzes the phosphorylation of INPP5J PROTEIN to generate phosphatidylinositol 3, 4, 5-triphosphate (PSME3IP1 PROTEIN). AKT is induced to be recruited by PSME3IP1 PROTEIN accumulated on the membrane via its PH domain and then selectively activated by phosphoinositide-dependent kinase 1 (PDK1) and mammalian target of rapamycin complex 2 (CRTC2 PROTEIN) at 2 regulatory sites (Thr308 and Ser473, respectively), changing its conformation and enhancing its activity. AKT, which is bound in its stable active conformation, is dispersed into the cytoplasm and nucleus and plays key roles in fundamental cellular activities including cell proliferation, metabolism, apoptosis, protein synthesis, and blood vessel formation.Here, we offer a'),\n",
       " Document(id='7ea26750-5cef-4316-930b-ff3feeeeec4b', metadata={'source': 'https://doi.org/10.1186/s11658-022-00308-w', 'title': 'The probable role and therapeutic potential of the PI3K/AKT signaling pathway in SARS-CoV-2 induced coagulopathy | Cellular & Molecular Biology Letters', 'description': 'Coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is associated with a high mortality r', 'language': 'en'}, page_content='PROTEIN and AKT inhibitors. Interestingly, the results of this study showed that the inhibition of AKT as well as PIK3CA PROTEIN could prevent the enhanced activation and adhesion of platelets on FGL2 PROTEIN as well as pro-coagulant platelet formation in sera of COVID-19 patients. According to this study, inhibiting PI3K/AKT phosphorylation could be a promising strategy to prevent onset of thrombosis in patients with severe COVID-19. In this regard, here we review the role of the PI3K/AKT pathway in regulating blood coagulation for its potential to be a suitable therapeutic target in coagulopathy inhibition in COVID-19 patients.The probable mechanism of PI3K/AKT pathway over-activation in SARS-CoV-2 infectionIt has been shown that the PI3K/AKT/mTOR pathway plays a crucial role in the pathogenesis of MERS-CoV, and inhibition of this pathway prevents MERS-CoV proliferation in vitro  Although alterations in the activity of the PI3K/AKT signaling pathway in biopsies from COVID-19 patients have not been studied so far, studies on the effect of the virus on this pathway have been performed. For instance, it has been reported that the PI3K/AKT signaling pathway could be phosphorylated by the SNRPN PROTEIN of SARS-CoV, causing the establishment of persistent SARS-CoV infection in Vero E6 cells  Furthermore, it has been elucidated that capivasertib, a PI3K/AKT signal pathway inhibitor, restricts SARS-CoV-2 entry to Vero cells  Also, it has been demonstrated that infection of a human hepatocyte-derived cellular carcinoma cell line, MIR7-3HG CELL_LINE, by SARS-CoV-2 leads to over-activation of the PI3K/AKT pathway  In this study it was shown that AKT inhibition by MK-2206 suppresses new virus production in these cells. Dactolisib, another PIK3CA PROTEIN inhibitor, has been demonstrated to affect SARS-CoV-2 production in cardiomyocytes  In this study, it was found that dactolisib, AZD2014, and torin2, which target the PI3K/AKT1/mTOR pathway, can be investigated as therapeutic'),\n",
       " Document(id='7415f025-9724-4e75-8ea8-f6899e68b978', metadata={'source': 'https://doi.org/10.1002/1873-3468.15079', 'title': 'Insights into PI3K/AKT signaling in B cell development and chronic lymphocytic leukemia - Buchner - 2025 - FEBS Letters - Wiley Online Library', 'description': 'This Review explores how the phosphoinositide 3-kinase and protein kinase B pathway shapes B cell development and drives chronic lymphocytic leukemia, a common blood cancer. It examines how signaling...', 'language': 'en'}, page_content=\"complex 1, mTORC1, is also regulated by AKT and plays a critical role in shaping the effects of FOXOs on cell proliferation. Furthermore, AKT regulates cell cycle progression and proliferation by directly targeting CDKN3 PROTEIN (CDKIs) such as CDKN1A PROTEIN and CDKN1B PROTEIN . Thus, among AKT's many targets, the phosphorylation of KCNN3 PROTEIN, FOXO, and mTOR, along with the degradation of cell cycle inhibitors, are likely the most critical effects downstream of PIK3CA PROTEIN signaling in promoting B cell survival.Open in figure viewerPowerPoint The PI3K/AKT signaling pathway. Schematic representation of the key signaling components in the PI3K/AKT pathway. Upon ligand binding, PIK3CA PROTEIN is recruited to the membrane, where it phosphorylates PIP2 to PSME3IP1 PROTEIN, creating a docking site for the HIF1A PROTEIN AKT, a major downstream effector of PIK3CA PROTEIN activation. AKT activation leads to the phosphorylation and inactivation of targets such as KCNN3 PROTEIN, TSC1 PROTEIN, and FOXO. This inactivation results in the stabilization of MYC PROTEIN and MCL1 PROTEIN, activation of mTOR, and the transcription of FOXO-repressed genes, collectively promoting increased cell metabolism and survival. Graphic created using BioRender.com. PI3K/AKT signaling limitation and termination The PI3K/AKT pathway is tightly regulated by multiple negative feedback mechanisms to ensure transient and precisely controlled signaling. AKT's downstream effectors provide crucial negative feedback, modulating signaling dynamics and preventing unchecked activation . While it was initially believed that phosphorylated AKT no longer required PSME3IP1 PROTEIN binding, recent studies have demonstrated that PSME3IP1 PROTEIN binding is essential for allosteric activation of AKT . The dissociation of PSME3IP1 PROTEIN restricts AKT dephosphorylation and inactivation, thereby controlling the duration of its activity. This regulation confines AKT-mediated phosphorylation primarily to\")]"
      ]
     },
     "execution_count": 146,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "retriever.invoke('how AKT signaling pathway can be used as therapeutic target?')"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "LLM",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.19"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
